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UNVEILING THE POLYMERASE COMPLEX OF NEGATIVE STRANDED RNA VIRUSES

by

CHELSEA SEVERIN

Under the Direction of Ming Luo, Ph.D.

ABSTRACT
Negative stranded RNA viruses (NSVs) are among the most common human pathogens
which cause pandemics and epidemics. This group includes many notable members such as
influenza, mumps and Ebola viruses. These viruses are identifiable by their negative polarity
genome which is associated with the nucleocapsid (NP) protein and assembled into higher order
structures. The RNA-nucleocapsid complex or ribonucleoprotein (RNP) serves as the template
for transcription and replication by the viral RNA-dependent RNA polymerase (vRdRp). Though
progress has been made in the study of these viruses, knowledge is lacking with regards to the
polymerase complex. Here, we utilize structural biology and mutational analysis to identify
components of the polymerase complex that will be targets for drug design.

NSVs typically cause high mortality outbreaks by transmission from animal reservoirs. In
fact, in 2013 H7N9 avian influenza A virus emerged as human infections and in 2017 the
number of infections raised to 688. This reaffirms that influenza virus is a global health threat
and requires antiviral drugs in the effort to control influenza virus. Frequently used anti-influenza
drugs target neuraminidase; however, there have been strains that show resistance to these
neuraminidase inhibitors. The PB2cap binding domain of the influenza RNA polymerase is an
innovative target for development of anti-influenza drugs. In this study, we have solved the
crystal structure of the PB2cap binding domain of influenza A H1N1 virus alone and in complex
with its binding partner. Utilizing this structure, we have identified critical interactions that will
aid in the design of antivirals.
The emergence of mumps virus outbreaks throughout the United States in the past five
years indicates that the MMR vaccine is not the most efficient source of protection and reaffirms
the need for inhibitors that target the virus. Here, we have utilized cryogenic electron microscopy
(cryoEM) to analyze the RNA encapsidation of mumps virus nucleocapsid and mutational
analysis of the phosphoprotein to probe the interactions involved in uncoiling the nucleocapsid.
This data adds to the available knowledge about mumps virus infection and could potentially aid
in the design of inhibitors.

INDEX WORDS: Negative-stranded RNA virus, Influenza virus, Mumps virus, RNA-dependent
RNA polymerase, Nucleocapsid, Phosphoprotein, Antiviral, Drug design

UNVEILING THE POLYMERASE COMPLEX OF NEGATIVE STRANDED RNA VIRUSES

by

CHELSEA SEVERIN

A Dissertation Submitted in Partial Fulfillment of the Requirements for the Degree of
Doctor of Philosophy
in the College of Arts and Sciences
Georgia State University
2020

Copyright by
Chelsea Severin
2020

UNVEILING THE POLYMERASE COMPLEX OF NEGATIVE STRANDED RNA VIRUSES

by

CHELSEA SEVERIN

Committee Chair:

Ming Luo

Committee:

Jenny Yang
Kathryn Grant

Electronic Version Approved:

Office of Graduate Studies
College of Arts and Sciences
Georgia State University
December 2020

iv
DEDICATION

I owe everything that I am and everything that I am becoming to the strongest women I know my mother Lynda and aunt Shirley. I would not have been able to complete this journey without
your support.

“As iron sharpens iron, so one man sharpens another” Proverbs 27:17

v
ACKNOWLEDGEMENTS
After graduating with my bachelor’s degree, I knew I wanted to do work that impacted
the world and that a PhD degree would be a stepping-stone on that journey. I would not have
been able to see my dream become a reality it was not for the supportive group of individuals
that have provided a listening ear, a comforting shoulder and stern words. None of this work
would have been possible without the financial support of the Chemistry Department and the
Center for Diagnostics and Therapeutics at Georgia State University.
I am deeply indebted to my advisor Dr. Ming Luo, who has been patient with me
throughout my PhD while I found my footing. When I started in August 2014, I was doe-eyed
and blissfully unaware about the effort that this degree would require. Dr. Luo never allowed me
to settle for less and taught me what I needed to do to succeed as a doctoral researcher. Through
his actions, he has shown me what it takes to be not only a good researcher but a good mentor. I
would also like to thank my committee members Dr. Katherine Grant and Dr. Jenny Yang. Dr.
Grant and Dr. Yang exemplify what it means to be a successful woman in science.
To the Luo lab members, past and present, thank you. I do not think I would have been
able to accomplish anything if it was not for the amazing group of individuals who I have shared
a workspace with. Over these past years I have gotten to know some amazing men and women
some of which have become close friends. Thank you all for being a sounding board for my
ideas and for providing valued advice.
Lastly, I want to salute my family. To my cancer fighting mother, I am so grateful to have
you around. Mom, you have shown me the meaning of resilience. I am also thankful for my aunt
Shirley who has supported me in all ways throughout this time. Finally, to my dear husband

vi
Rotando you are the epitome of a compassionate spouse. You are more supportive than I could
ever give you credit for. Thank you all for sticking through this journey with me.

vii
TABLE OF CONTENTS
ACKNOWLEDGEMENTS .........................................................................................................V
LIST OF TABLES ...................................................................................................................... XI
LIST OF FIGURES .................................................................................................................. XII
LIST OF ABBREVIATIONS ................................................................................................. XIII
1.

INTRODUCTION ............................................................................................................ 1
1.1

Group V Viruses: Negative Strand RNA Viruses ..................................................... 2

1.2

Orthomyxoviridae – Influenza Viruses........................................................................ 3

1.2.1

Overview of Virus Structure and Genome Organization ........................................ 4

1.2.2

Influenza A Virus Lifecycle ..................................................................................... 5

1.2.3

Inhibitors of Influenza Virus ................................................................................... 8

1.3

Paramyxoviridae – Mumps Virus .............................................................................. 11

1.3.1

Mumps Viral Replication Cycle ............................................................................. 12

1.3.2

Polymerase Complex .............................................................................................. 13

1.3.3

Mumps Virus Prevention - MMR Vaccine ............................................................ 15

1.4
2.

Scope of Research ....................................................................................................... 16
THE CAP-BINDING SITE OF INFLUENZA VIRUS PROTEIN PB2 AS A DRUG
TARGET.......................................................................................................................... 26

2.1

Abstract ....................................................................................................................... 26

2.2

Introduction ................................................................................................................ 27

viii
2.3

Materials and methods .............................................................................................. 30

2.3.1

Protein expression and purification ...................................................................... 30

2.3.2

Crystallization and structure analyses ................................................................... 30

2.4

Results and discussion ............................................................................................... 31

2.4.1

The cap-binding site in PB2 of A/California/07/2009 .......................................... 31

2.4.2

Interactions between m7GTP and the cap-binding site ......................................... 33

2.4.3

Comparisons with PB2cap inhibitors .................................................................... 36

2.4.4

Differences from PB2cap of influenza B virus ..................................................... 37

2.4.5

Comparisons with human cap-binding proteins ................................................... 38

3.

RELEASING THE GENOMIC RNA SEQUESTERED IN THE MUMPS VIRUS
NUCLEOCAPSID .......................................................................................................... 47

3.1

Abstract ....................................................................................................................... 47

3.1.1

Importance .............................................................................................................. 48

3.2

Introduction ................................................................................................................ 48

3.3

Materials and methods .............................................................................................. 51

3.3.1

Expression and purification of recombinant MuV N protein .............................. 51

3.3.2

Cryo-EM structure of the empty MuV N assembly. .............................................. 51

3.3.3

Minigenome assays................................................................................................. 52

3.4

Results ......................................................................................................................... 53

3.4.1

Structure of a truncated empty capsid. .................................................................. 53

ix
3.4.2

Comparison with the authentic nucleocapsid. ...................................................... 54

3.4.3

How is the encapsidated genomic RNA unveiled by the viral polymerase? ......... 55

3.4.4

Residues in the loop-helix α7 are critical. ............................................................. 57

3.5
4.

Discussion .................................................................................................................... 58
PROBING THE ROLE OF THE PHOSPHOPROTEIN AMINO TERMINAL END
IN THE UNCOILING OF THE NUCLEOCAPSID ................................................... 64

4.1

Abstract ....................................................................................................................... 64

4.2

Introduction ................................................................................................................ 64

4.3

Materials and Methods .............................................................................................. 67

4.3.1

Molecular Biology .................................................................................................. 67

4.3.2

Computer aided studies .......................................................................................... 68

4.3.3

Protein expression and purification ...................................................................... 68

4.3.4

Protein binding assay ............................................................................................. 70

4.3.5

Thermal shift assay................................................................................................. 70

4.4

Results ......................................................................................................................... 71

4.4.1

Identification of N-terminal residues of P involved in the potential NLP binding
site ........................................................................................................................... 71

4.4.2

Residues in loop are necessary for NLP-P110 interaction in pulldown assay..... 72

4.4.3

Effects of targeted mutations on thermal stability of NLP-P110 interaction ...... 72

4.4.4

Alanine variants affect the thermal release of RNA from the NLP ..................... 73

x
4.5
5.

6.

Discussion .................................................................................................................... 74
RESEARCH CHALLENGES AND IMPACT............................................................. 81

5.1

Crystallization of PB2 cap binding protein ............................................................. 81

5.2

Implications for Design of inhibitors that target influenza viruses A & B ........... 81

5.3

Viral RNA sequestered within the Paramyxovirus Nucleocapsid ......................... 82

5.4

Uncoiling the MuV Nucleocapsid ............................................................................. 83

5.5

Implications for design of antivirals and vaccine development of MuV ............... 83
CONCLUSIONS ............................................................................................................. 84

REFERENCES............................................................................................................................ 86

xi
LIST OF TABLES
Table 1-1 FDA Approved Influenza Drugs .............................................................................. 21
Table 2-1 Data-collection and refinement statistics ................................................................. 41
Table 4-1 Summary of Affinities and Thermal Release of RNA ............................................ 80

xii
LIST OF FIGURES
Figure 1-1 Baltimore Viral Classification ................................................................................. 18
Figure 1-2 Genome Organization of Influenza Viruses........................................................... 19
Figure 1-3 Cap Snatching Polymerase ...................................................................................... 20
Figure 1-4 Drug Resistance in Neuraminidase ......................................................................... 22
Figure 1-5 Drug Resistance in M2 channel............................................................................... 23
Figure 1-6 The Family Paramyxoviridae .................................................................................. 24
Figure 1-7 Mumps virus Outbreaks .......................................................................................... 25
Figure 2-1 The cap-binding site in PB2cap............................................................................... 40
Figure 2-2 Structure of Influenza A cap binding site .............................................................. 42
Figure 2-3 Comparing bound and unbound PB2cap .............................................................. 43
Figure 2-4 Comparison of the PB2cap cap-binding site. ......................................................... 44
Figure 2-5 Comparing Influenza A and B cap binding ........................................................... 45
Figure 2-6 Human cap binding proteins ................................................................................... 46
Figure 3-1 CryoEM Structure of N379 ....................................................................................... 60
Figure 3-2 Comparing empty capsid with that of the authentic ............................................. 61
Figure 3-3 RNA binding per N subunit..................................................................................... 62
Figure 3-4 Minigenome assay of mutants ................................................................................. 63
Figure 4-1 Homology Model of NCORE-P110 complex.............................................................. 77
Figure 4-2 Pulldown assay.......................................................................................................... 78
Figure 4-3 Thermal Stability Assay........................................................................................... 79

xiii
LIST OF ABBREVIATIONS
Centers for Disease Control (CDC)
Cryogenic electron microscopy (cryoEM)
Deoxyribonucleic Acid (DNA)
Double Stranded DNA (dsDNA)
Double Stranded RNA (dsRNA)
Glycoprotein (G)
Large protein (L)
Matrix-protein (M)
Messenger Ribonucleic Acid (mRNA)
Mumps Virus (MuV)a
Negative stranded RNA viruses (NSVs)
Nucleocapsid protein (NP)
Nucleocapsid-like Particle (NLP)
Phosphoprotein (P)
Polymerase Basic 1 protein (PB1)
Polymerase Basic 2 cap binding protein (PB2cap)
Protein Databank (PDB)
Ribonucleic Acid (RNA)
Ribonucleoprotein (RNP)
Single Stranded DNA (ssDNA)
Single Stranded RNA (ssRNA)
Thermal Shift Assay (TSA)
Viral Ribonucleic Acid (vRNA)
Viral RNA Dependent RNA polymerase (vRdRp)
World Health Organization (WHO)

1
1. INTRODUCTION
The current coronavirus pandemic highlights how unprepared we are to tackle emerging
viruses. These pathogens are notorious for having a negative impact on public health and
agricultural commerce. The International Committee on Taxonomy of Viruses (ICTV) is
responsible for the formal taxonomic classification of viruses. Although this method of
classification is necessary to organize newly discovered viruses to track their evolutionary
relationships, the Baltimore system is a simpler method of grouping viruses (1).
In his landmark article, David Baltimore proposed a viral classification system based on
the viral genome and the method of replication (Figure 1-1). For efficient viral infection, all
viruses must synthesize mRNA to produce viral proteins. Therefore, Baltimore designed his
classification system to give mRNA a central role in viral replication.
Group I viruses are pathogens which have a double-stranded DNA (dsDNA) genome.
These viruses utilize the host cell replication machinery (RNA polymerase II) to transcribe the
viral DNA into mRNA. Examples of Group I viruses include herpes simplex I (HSV-1) and
varicella zoster virus (2, 3). Viruses belonging to the group II include the family Parvoviridae
which includes canine parvovirus which is a highly contagious infection in dogs. This group
possesses a single-stranded DNA (ssDNA) which replicates mostly within the nucleus forming a
dsDNA intermediate in the process.
Viruses of group III to group V contain an RNA genome and replicate primarily in the
cytoplasm of the host cell. Group III viruses possess a double-stranded RNA (dsRNA) genome
which is used to synthesize mRNA and protein synthesis. Group IV viruses have a positive sense
single-stranded RNA (ssRNA) as their genome. For replication, these viruses must generate a
negative sense anti-genome which acts as a template for generation of the positive sense genome.
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Additionally, the positive sense genome can be directly transcribed by host ribosomes to produce
viral proteins. Examples of this class of viruses include the Flaviviridae and Picornaviridae
families. The Flaviviridae family includes several important human pathogens such as Zika
virus, dengue virus and yellow fever virus. Viruses which possess a negative sense singlestranded RNA (nsRNA) as their genome are placed into group V. Prototypical members of this
group include vesicular stomatitis virus (VSV), mumps virus (MuV) and influenza viruses. The
viral genome of group V viruses must first be transcribed into the positive sense for translation of
viral proteins.
Reverse transcription is utilized by groups VI and VII viruses to replicate their genomes.
Viruses belonging to group VI have a positive sense ssRNA as their viral genome. These viruses
use reverse transcriptase to transcribe their RNA genome into a DNA/RNA hybrid intermediate
which serves as a template to form dsDNA which is then converted to mRNA. One of the most
notable members of this group is human immunodeficiency virus (HIV). Unlike group VI
viruses, viruses classified into group VII possess a dsDNA genome and utilize reverse
transcription to generate mRNA.
1.1

Group V Viruses: Negative Strand RNA Viruses
Viruses belonging to group V are also referred to as Negative Stranded RNA Viruses

(NSVs). These viruses consist of many notable human pathogens such as Ebola, influenza and
mumps viruses and agricultural pathogens such as VSV. These viruses utilize a negative polarity
ssRNA as their genome which is associated with nucleocapsid (N) protein to form a
ribonucleoprotein (RNP) complex. NSVs can further be divided into two groups based on the
segmented nature of their genome. The non-segmented NSVs (nsNSVs) include the
Bornaviridae (Borne disease virus), Filoviridae (Ebola virus), Paramyxoviridae (mumps and
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measles viruses) and Rhabdoviridae (rabies virus) families. Whereas the segmented NSVs
(sNSVs) include the Arenaviridae (Machupo virus), Bunyaviridae (Rift valley fever virus) and
Orthomyxoviridae (influenza viruses).
Despite their differences in genome segments, the viral RNA of NSVs is encapsidated by
the nucleocapsid protein during the span of the viral life cycle. This ribonucleoprotein (RNP)
complex is the only functional form of the genome for viral replication. In nsNSVs, the RNP
complexes form helical or ring shaped structures which are typically linear and relatively rigid
(4). The RNPs of sNSVs have a more flexible circular conformation which is induced by the
binding of the polymerase to the 5’ and 3’ end of the viral RNA (vRNA) segments (5, 6).
Although both nsNSVs and sNSVs package a polymerase within the virus particle, they
differ in the capping mechanism of mRNA transcripts. For sNSVs transcription is initiated by
acquiring a capped primer derived from the host cell nascent mRNA (7–11). The polymerase of
nsNSVs possess the ability to cap mRNA transcripts in a mechanism that is distinct from viral
and eukaryotic systems (10, 12, 13). The unique nature of the polymerase complex of NSVs
make it a viable target for the development of inhibitors that disrupt viral replication and
transcription.
1.2

Orthomyxoviridae – Influenza Viruses
Influenza viruses are amongst the most contagious respiratory viruses that infect humans

and are notorious for yearly outbreaks. In addition to annual spread, occasionally these viruses
are responsible for severe pandemics. The 1918 H1N1 often referred to as “Spanish flu” was
responsible for about 50 million deaths worldwide with about 675,000 occurring in the United
States (14, 15). More recently, the 2009 H1N1 pandemic resulted in an estimated 61 million
infections and over 12000 deaths in the United States (16). These viruses pose a significant
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public health burden; therefore, an efficient arsenal of therapeutics is necessary to treat this
disease.
Influenza viruses belong to the Orthomyxoviridae family of viruses. These viruses are
characterized by their segmented, negative-sense, single-stranded RNA genome. Within this
family there are five different genera: the influenza viruses A, B, C and D; Thogotovirus; and
Isavirus. Influenza A viruses are responsible for epidemics and pandemics and are known
pathogens of humans, horses and fowls. Influenza B viruses occasionally cause epidemics and
only infect humans. Influenza C viruses are known human and pig pathogens, but they rarely
cause disease. Influenza D virus was recently isolated in cattle and swine; no human infections
have been observed. Although, Thogotovirus and Isavirus pose a significant threat to human
health and agricultural economies, the primary focus of this review will be on influenza A
viruses and to a lesser extent influenza B virus. Furthermore, influenza C viruses are
morphologically and genetically distinct from influenza A and B viruses and are generally
asymptomatic and will not be discussed extensively.
1.2.1

Overview of Virus Structure and Genome Organization
Types A and B influenza viruses are indistinguishable when analyzed by electron

microscopy, but the virion organization differs slightly (6, 17). Influenza A virus has the
hemagglutinin (HA), neuraminidase (NA) and M2 proteins inserted into the host cell derived
lipid membrane. The matrix protein (M1) lies beneath the envelope and the core of the particle
consists of 8 viral RNA segments, the NEP/NS2 (nuclear export protein/nonstructural protein 2)
and the polymerase complex (polymerase acid [PA]; polymerase basic 1 [PB1]; and polymerase
basic 2 [PB2]). Influenza B virions have four proteins in their envelope: HA, NA, NB and BM2
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(18). With regards to genome organization, influenza A and B viruses both possess only eight
viral RNA segments that code for one or more proteins (Figure 1-2).
1.2.2

Influenza A Virus Lifecycle

1.2.2.1 Virus Entry and Nuclear Import
Viral infection is initiated by HA binding to sialic acid moieties on the cell surface.
Human influenza viruses typically bind to N-acetylneuraminic acid attached to the penultimate
galactose sugar by an α2,6 linkage. This binding induces endocytosis of the virion through
clathrin-mediated process or micropinocytosis (18).
Once the virion is enclosed in an endosome, fusion of the viral membrane is induced by
structural changes in HA due to the low pH. The HA0 precursor is cleaved into HA1 and HA2
subunits. The structural change of the HA exposes the HA2 fusion peptide which enables the HA
to interact with the endosomal membrane. Additionally, the conformational change in HA opens
the M2 ion channel which allows an influx of H+ ions from the endosome into the viral core.
This decrease in pH releases the viral RNP (vRNP) from the M1 protein and allows free vRNP
complex to be released into the cytoplasm
Viral replication and transcription are dependent on the host cell’s nuclear functions;
therefore, upon release into the cytoplasm the vRNPs are transported to the nucleus. The vRNP
complex consists of the vRNA encapsidated by NP and the polymerase complex which binds to
the ends of the vRNA. Each protein within the vRNP contains a nuclear localization signal
(NLS); however, it seems that the NLS on NP is necessary for viral RNA import (19). The
transport of vRNPs across the nuclear membrane is mediated by the importin α family.
Karyopherin α binds directly to the NLS on NP and then recruits karyopherin β which opens the
nuclear pore and allows vRNP transport into the nucleus.
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1.2.2.2 Cap Snatching Viral RdRp
Once within the nucleus, the viral RNA serves as a template for mRNA synthesis. As
previously described, the vRNP exists as a complex in which the RNA is encapsidated by NP
and forms a helical hairpin that is attached to the polymerase complex. It is the NP coated RNA
not the naked RNA that serves as a template for transcription. Influenza viral RNA dependent
RNA polymerase (vRdRp) is composed of three proteins (Figure 1-3): PB1, PB2 and PA (20).
This polymerase complex hijacks the host cell machinery during the synthesis of mRNA, a
process referred to as cap snatching. PB1 initiates transcription by binding to the terminal ends of
the vRNA. This binding induces a conformational change in the complex which allows the PB2
protein to bind to the cap of host cell pre-mRNAs (21). Studies have shown that the vRdRp
interacts with the large subunit of cellular DNA-dependent RNA polymerase II (Pol II) in its
transcriptionally active, hyperphosphorylated form. The PB2 protein initiates transcription by
binding to the 5’,7-methylguanosine cap of nascent cell mRNA molecules. PA endonuclease
domain then cleaves the cellular mRNA about 10 to 15 nucleotides downstream of the cap. This
capped primer is then transferred to the active site of the PB1 subunit and is used to initiate viral
transcription. The addition of a guanine or cytosine residue to the end of the primer initiates
elongation by PB1 until a stretch of five to seven uridine residues are encountered which is a
polyadenylation signal.
In addition to serving as a template for mRNA synthesis, the vRNA also acts as a
template for the synthesis of positive sense replication intermediate RNA which is used for RNA
genome synthesis. This process is a two-step primer independent mechanism. The switch from
transcriptase to replicase mode is poorly understood, but some studies suggest that the
concentration of soluble NP plays a role (18). Firstly, the vRNPs are used to generate a positive
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sense complementary RNA (cRNA) intermediate. To begin, the 3’ end of the vRNA is
transported to the active site of the complex, where a pppApG dinucleotide is aligned to residues
U1 and C2 of the vRNA. The PB1 protein elongates the cRNA strand and the cRNA is
encapsidated by NP as it is synthesized. This complementary RNP is then used as a template for
vRNA synthesis. For vRNA production, a pppApG dinucleotide is formed on residues U4 and
C5. The pppApG product is then subsequently U1 and C2 for elongation. It is unknown at where
and how the 5’ end of the cRNA binds to the polymerase; however, several models have been
proposed. The newly synthesized vRNA is encapsidated by NP.
1.2.2.3 Nuclear Export of Ribonucleoproteins
The plasma membrane is the site of assembly and budding for influenza viruses.
Therefore, it is necessary to export the newly synthesized vRNPs to the cytoplasm. Transport of
vRNPs is facilitated by two proteins: M1 and NEP/NS2. Current models of nuclear export
suggest that M1 binds to vRNPs and causes dissociation of vRNPs from the nuclear matrix,
thereby downregulating transcription(22, 23). Furthermore, it has been shown that the NEP/NS2
protein interacts with chromosome region maintenance 1 (CRM1) and several nucleoporins. The
data suggests that a ‘daisy-chain’ complex of vRNP, M1, NEP/NS2 and CRM1 is formed for
nuclear export (24).
Influenza virus particles assemble and bud from the apical membrane of polarized cells.
The HA, NA, and M2 proteins are transported to the assembly site where later the vRNPs are
translocated by Rab11. The eight segments of the viral genome are packaged, and budding is
induced by the M1 protein. During budding, HA binds to the sialic acid containing receptors on
the cell surface. For release of the virion from the infected cell, NA cleaves these sialic acid
residues.
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1.2.3

Inhibitors of Influenza Virus
The first line of defense against influenza epidemics and pandemics is the annual flu

vaccine. This seasonal vaccine is designed each year using surveillance data of circulating
viruses and predictions about the ones which are most likely to spread in the upcoming season;
however, there are some limitations of the annual vaccine (25). Candidate viruses for vaccines
are primarily produced in eggs which provides a problem for preparing vaccines for viruses that
grow poorly using this method (e.g. H3N2 viruses). Furthermore, FDA regulations makes it
difficult to prepare a candidate vaccine for viruses that spread later in the season. Fortunately,
there are three classes of FDA approved influenza antivirals: neuraminidase inhibitors; M2 ion
channel inhibitors; and cap-dependent endonuclease inhibitors (Table 1-1).
1.2.3.1 Neuraminidase inhibitors
Neuraminidase supports viral infection by cleaving sialic acid on cell surface receptors to
allow release of newly formed viral progeny. The 3D structure of NA allowed structure guided
design of therapeutics that inhibit the enzymatic activity of the protein. Historically, the first
neuraminidase inhibitor (NAI) discovered was 2,3-dehydro-2-deoxy-N-acetylneuraminic acid
(DANA); however, it has low inhibition of NA (31). The crystal structure of NA in complex with
DANA served as a basis for the design of the three currently approved NAIs: zanamivir
(Relenza); oseltamivir (Tamiflu); and peramivir (Rapivab).
The crystal structure of the NA-DANA complex revealed that the active site of the
protein contained an empty pocket and the C4 hydroxyl group position could accommodate a
larger substitution. Subsequently, zanamivir was designed with a 4-guanidino group at the C4
hydroxyl group position to improve the affinity for the enzyme. Zanamivir is indicated for
treatment of type A and B viruses in adults and children seven years and older. The drug is
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administered directly to the site of infection as an oral inhalation powder due to its highly polar
nature and rapid excretion.
Oseltamivir was developed as an orally bioavailable inhibitor of NA. The drug was based
upon the structure of zanamivir, in which the C4 hydroxyl group was replaced by an amino
group and the glycerol side chain was replaced with a pentyl ether side chain (18, 26). Although
oseltamivir was designed to increase oral bioavailability, studies showed that in its active form
the drug had poor oral bioavailability. Therefore, the drug is delivered as the ethyl-ester prodrug
which is converted to the active drug by hepatic esterases.
Peramivir is the third FDA approved NAI. This drug is a cyclopentane derivative with a
C4-guanidino substituition and bulky hydrophobic side chain which resembles the structures of
both zanamivir and oseltamivir (18). Peramivir is administered intravenously for treatment of
influenza A viruses.
Resistance to NAIs is primarily due to mutations in NA. To date, viruses have been
isolated from patients which have reduced susceptibility to all approved NAIs (27). A(H3N2)
viruses with R292K and E119V mutants have reduced susceptibility to oseltamivir and
peramivir. Zanamivir remains effective against E119V mutants but has reduced binding to
R292K mutants. Additionally, an influenza B isolate with S250G mutation was found to have
decreased effectiveness; however, oseltamivir remained a potent inhibitor of NA (28).
A H274Y mutation near the active site of the enzyme confers high resistance to
oseltamivir in N1 viruses including 2009 pandemic H1N1. This H275Y mutant confers
resistance to peramivir to a lesser extent but viruses with this mutation remain susceptible to
treatment with zanamivir. Structural studies indicate that the tyrosine residue moves the carboxyl
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group of Glu27 further into the binding site (Figure 1-4) which disrupts the hydrophobic pocket
(29).
1.2.3.2 M2 Ion Channel Inhibitors Resistance
Amantadine (Symmetrel) and rimantadine (Flumadine), also referred to as the
adamantanes, inhibit viral infection by binding to the M2 protein thereby preventing uncoating
(30). Adamantanes were the first approved drugs for treatment of influenza virus infections.
These antivirals are indicated for treatment for type A viruses and are not effective against
influenza B viruses. Approximately 100% of circulating influenza A viruses have conferred
resistance against the adamantanes. As a result, the Centers for Disease Control and Prevention
has issued an advisory against the use of the adamantanes for influenza A treatment. The reduced
susceptibility of influenza A virus to the adamantanes has been associated with a S31N mutation
(31, 32). The presence of Asn seems to open the pore to allow protons to flow through the
channel in the presence of the drug (Figure 1-5).
1.2.3.3 Cap-dependent endonuclease inhibitors
At the time of our studies, there were no FDA approved drugs that targeted the influenza
polymerase complex. However, in 2018, baloxavir marboxil (BXM), a prodrug of baloxavir acid
(BXA), received regulatory approval for the treatment of influenza A and B viruses in patients
12 and older. BXM inhibits the PA endonuclease of the polymerase complex and prevents viral
transcription. The drug was developed by rational drug design using the pharmacophore structure
of the strand transfer inhibitor of HIV, dolutegravir.
Reduced susceptibility of BXM has been observed in type A and B viruses carrying an
I38T mutation. Structural analyses of the mutant and wild type PA bound to BXA illustrated the
effects of this change on drug binding (33). The structure of the PA I38T mutant bound to BXA
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indicates that the presence of the more polar threonine residue at position 38 reduces Van der
Waals interactions with the compound.
1.3

Paramyxoviridae – Mumps Virus
The Paramyxoviridae family are enveloped viruses which possess a non-segmented,

single stranded negative polarity RNA genome. This family includes many notable pathogens
which have an impact on agricultural livestock and public health such as measles, mumps and
Newcastle disease. The family Paramyxoviridae is further divided into the Avulavirinae,
Rubulavirinae, Metaparamyxovirinae and Orthoparamyxovirinae subfamilies (Figure 1-6).
Mumps virus (MuV) belongs to the subfamily Rubulavirinae and Orthorubulavirus
genus. The first documented infection of MuV was described by Hippocrates in the 5 th century
BCE (34), in which he described an illness associated with parotitis and orchitis. However, viral
etiology was not described until 1934 when Johnson and Goodpasture showed that the filter
sterilized virus particles could be transmitted from infected patients to rhesus monkeys (35).
Viral infection is characterized by inflammation of the parotid glands but swelling in other
organs including the brain, heart and testicles has been observed.
MuV virions are pleomorphic and range in size from 100 to 600 nm (36). Within the viral
particles is the viral genome which is encapsidated by the N protein to form a long helical RNP
complex. The MuV genome is a negative sense, nonsegmented genome consisting of 15,384
nucleotides. The genome consists of seven continuously linked genes that encode nine proteins
in the order: nucleocapsid protein, V protein/phosphoprotein (P)/I protein, matrix (M) protein,
fusion (F) protein, small hydrophobic (SH) protein, hemagglutinin-neuraminidase (HN), and
large (L) protein.
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1.3.1

Mumps Viral Replication Cycle
Mumps virus infections enter host cells via receptor mediated endocytosis. Entry is

mediated by attachment of HN proteins to sialic acid receptors on the cell surface. In addition to
receptor binding to sialic acid, HN protein is also responsible for cleavage of sialic acid and
fusion. Once the virus has been attached to the host cell, the F proteins initiate viral entry by
fusion of the virion envelope and the host cell plasma membrane. The fusion process is driven by
conformational changes in the F proteins into lower energy hairpin states at a neutral pH (36).
Consequently, the negative sense nucleocapsid is released into the cytoplasm. Primary
intracellular replication then occurs with the vRdRp transcribing the viral genome within the
ribonucleoprotein (RNP) into 5’ capped and 3’ polyadenylated mRNAs. These viral mRNAs are
then translated by host ribosomes to produce viral proteins for genome replication. The
accumulation of high levels of N protein mediates the switch of the vRdRp to replication mode
and synthesizes full length positive-sense antigenome which is subsequently used for synthesis
of full-length negative-sense progeny genomes (37). These progeny genomes can then be utilized
as a template for secondary transcription for production of additional antigenomes or assembled
into virions. The M protein orchestrates assembly of the viral proteins and RNPs at the plasma
membrane of the infected cell and the progeny virions are released via a budding process.
1.3.1.1 Nucleocapsid Protein
The vRdRp initiates transcription by binding to the NP encapsidated viral RNA to
transcribe the genome into 5’ capped and 3’ polyadenylated mRNAs. The NP protein of MuV is
the first transcribed gene in the viral genome and is 549 amino acid residues long. NP binds to
the full-length negative-sense genome and positive-sense anti-genome to form the
transcriptionally active template for replication. Formation of the helical RNP is suggested to
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serve several purposes including protection from nucleases. Structural imaging of the RNP
indicates that the NP protein binds to approximately six nucleotides per subunit and 13 NP
subunits constitutes one turn of the helical RNP. Studies have shown that the overall genome
length must be a multiple of six for efficient replication (38).
The structure of the nucleocapsid protein has been solved for several members of the
Paramyxoviridae family. Analyses of these structures suggest that they share common features:
an N-terminal domain and C-terminal domain in its core which is composed of mostly α–helices.
The 3D structure of the NP protein of MuV has not been solved; however, recently the structure
of the N-terminal core of NP of parainfluenza virus-5 (PIV) was solved to 3.11 Å (39).
Analyses suggest that the P protein tethers the polymerase complex onto the nucleocapsid
template through interaction with the C-terminal domain of P (PCTD). Furthermore, electron
microscopy has revealed that the helical RNP is unwound by binding of the N-terminal domain
of P (PNTD) to the nucleocapsid protein (40). In infected cells, the nucleocapsid protein also exists
in a soluble, monomeric form (N0) that is not associated with RNA. These N0 molecules have
been found associated with the P protein for many paramyxoviruses including measles virus
(MeV), sendai virus (SeV) and PIV5. The current data suggests that N 0 binds to nascent viral
RNA and P binds to N0 to prevent binding to non-specific cellular RNA.
1.3.2

Polymerase Complex
The vRdRp is a complex formed between the large (L) and P proteins. The L protein of

mumps virus is a 2261 amino acid residues long which ranges in size from 160 to 200 kDa.
Catalytic activity for RNA synthesis, polyadenylation, capping and methylation is included in the
L protein. Analyses of the L proteins of paramyxoviruses indicate that the viruses share six
conserved domains (I-VI) which are responsible for the multiple enzymatic capabilities of the
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protein. However, the exact functions of each domain in the protein has not been extensively
studied. Domain II has been suggested to be a possible RNA binding site due to its large net
positive charge. Domain III is involved in phosphodiester bond formation. Domains V is thought
to be responsible for the unique capping mechanism of the viral polymerase. Domain VI has
been associated with methyltransferase activity. The function of Domains I, IV but mutagenic
studies have suggested that these domains may play a role in the switch from replicase to
transcriptase mode.
Self-oligomerization in the L protein and in complex with other viral proteins is also
observed. The L-P protein complex is required for viral replication. The complex is necessary to
tether the polymerase onto the nucleocapsid template. Furthermore, studies show that P-L
interaction is necessary to stabilize the L protein; however, the actual domain of L which
interacts with the P protein has not been determined.
The P protein is an important cofactor of the L protein in MuV. The P protein is
transcribed from the V/P/I gene by addition of two guanine residues at the site 155. This edited
mRNA is translated into a polypeptide which is 41 to 47 kDa in size. In addition to its functions
in transcription and replication, the P protein binds to the nucleocapsid and tethers the
polymerase onto the nucleocapsid template. Extensive analyses indicate that the P protein is a
modular protein consisting of C- and N- terminal domains which are essential for transcription
and nascent chain assembly respectively (41). The interaction between the N-terminal domain of
the P protein and the N0 nascent chain leads to the formation of the complex that encapsidates
RNA during replication.
The MuV P protein has not been extensively studied like that of other paramyxoviruses
such as Sendai virus (SeV) and human respiratory syncytial virus (RSV). Although it is certain
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that the P protein is essential for viral RNA synthesis, the exact mechanism of the P protein has
not been elucidated.
1.3.3

Mumps Virus Prevention - MMR Vaccine
There are no FDA approved drugs or drugs that are being tested in clinical trials that

target MuV. Vaccination is the only method of protection against viral infection. Currently two
vaccines are approved to prevent MuV infection in the United States: M-M-R II and ProQuad.
Historically, M-M-R II was the first approved vaccine in 1967 for prevention of mumps viral
infection. M-M-R II is a trivalent combination live attenuated virus indicated for vaccination
against MeV, MuV and Rubella which is administered in a two-dose regimen. M-M-R II
contains sterile lyophilized preparations of ATTENUVAX (a line MeV derived from Enders’
attenuated Edmonston strain), MUMPSVAX (Jeryl Lynn strain of MuV) and MERUVAX II
(Wistart RA 27/3 strain of rubella virus). A single vaccine dose is 78% effective against the
virus, whereas two doses are 88% effective. ProQuad vaccine was FDA approved in 2005 for
prevention of measles, mumps, rubella and varicella in children 12 months through 12 years.
At the time of introduction of the M-M-R II vaccine, there were 152,209 reported cases
of mumps virus and 25 deaths associated with infection. Since the implementation of vaccination
measures, the incidence of mumps virus infections has steadily declined (Figure 1-7). Typically,
once immunized according to the ACIP recommended schedule, natural immunity to the virus is
lifelong.
Despite the efficacy of the vaccine large outbreaks of mumps virus has been recorded in
the United States. In 2006 a mumps virus epidemic was observed in Iowa where a massive
outbreak was noted on university campuses which ultimately spread to other states and resulted
in 6584 cases and one death due to infection. Most cases were observed in patients with an
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average age of 21 years of age of which 65% had a documented immunization history of
receiving two doses of the M-M-R II vaccine. Since infection spread to patients with the
recommended doses of vaccine, the ACIP recommended that a third dose of a mumps virus
containing vaccine be used in populations at an increased risk for infection.
1.4

Scope of Research
Waning immunity to the M-M-R II vaccine and the lack of efficient therapeutics that

target NSVs could become a public health crisis during epidemics and pandemics caused by
these viruses. The polymerase complex of these viruses has not been extensively studied. The
polymerase complex of NSVs is a potential target for drug design since viral infection is requires
the enzymatic activity of the polymerase and there is a low risk of off-target effects since the
structural organization of NSV polymerases are significantly different from those in mammalian
cells.
This body of work aims to investigate the biological properties of the vRdRp of NSVs for
design of more efficient antivirals. The interactions between the viral proteins of the polymerase
complex are necessary for viral infection. Thorough knowledge of the relationship between these
proteins is necessary to develop inhibitors that target the protein complex. This research includes
the following objectives:
1. To analyze the structure of the PB2cap binding protein for design of novel influenza
therapeutics. The structure of the PB2cap binding protein was studied alone and in
complex with a cap-analog. Several key residues were identified that would be critical for
rational drug design.
2. Structural analysis of RNA sequestered in the nucleocapsid protein of MuV. The
structure of the nucleocapsid protein has been solved for several members of the
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Paramyxoviridae family. Cryo-electron microscopy was used to identify a region within
the protein that is necessary for RNA release.
3. To characterize important residues in the amino terminal domain of the phosphoprotein
which are necessary for unveiling the encapsidated RNA. To identify interactions
between the nucleocapsid and phosphoproteins models of MuV nucleocapsid core and
phosphoprotein several alanine mutants were generated and probed by binding assays.
Furthermore, the effects of the variants on the thermal release of RNA was assessed.
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Figure 1-1 Baltimore Viral Classification
Schematic diagram of the Baltimore classification of viruses in which viruses are grouped by
method of viral mRNA synthesis (Virus, Baltimore Classification by Thomas Splettstoesser
licensed under CC BY-SA 3.0).
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Figure 1-2 Genome Organization of Influenza Viruses
Schematic representation of the viral RNA segments of influenza A (A) and influenza B (B)
viruses. Dashed lines represent introns.
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Figure 1-3 Cap Snatching Polymerase
Structure of bat influenza A polymerase in complex with vRNA promoter (PDB 4WSB)
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Table 1-1 FDA Approved Influenza Drugs
Structure
Neuraminidase inhibitors
Peramivir
(Rapivab)

Activity
Types A
and B

Drug Resistant Mutations
•
•

Zanamivir
(Relenza)

Types A
and B

•
•
•

Oseltamivir
(Tamiflu)

Types A
and B

•
•

H275Y mutation in NA
confers resistance to
influenza A/H1N1
R292K, N294S, E119V in
NA reduces viral
susceptibility in influenza
A/H3N2
NA R292K mutant decreases
efficacy against influenza
A/H3N2
D151G + H275Y
substitutions in NA of
pandemic 2009 H1N1 strains
S250G substitution in NA of
influenza B viruses
H275Y mutation in NA
confers resistance to
influenza A/H1N1
R292K, N294S, E119V in
NA reduces viral
susceptibility in influenza
A/H3N2

Polymerase inhibitors
Baloxavir marboxil
(Xofluza)

Types A
and B

•

E23K, I38T substitutions in
PA of A/H1N1, A/H3N2 and
B viruses are associated with
decreased efficacy of drugs

M2 ion channel inhibitors
Amantadine

Type A

•

Type A

•

S31N mutation in circulating
viruses confers resistance;
CDC does not recommend
use for treatment of influenza
viral infections
S31N mutation in circulating
viruses confers resistance;
CDC does not recommend
use for treatment of influenza
viral infections

Rimantadine
(Flumadine)
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Figure 1-4 Drug Resistance in Neuraminidase
Superimposition of the active site of wild-type (green) and mutant (blue) bound to oseltamivir (A)
and zanamivir (B). The H274Y structures indicate that the presence of the bulky tyrosine group
pushes Glu 276 further into the binding site which disrupts the hydrophobic pocket.
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Figure 1-5 Drug Resistance in M2 channel
Amantadine binding site within the M2 ion channel of an influenza A virus (A). Superimposition
of wild type (green) and mutant virus (purple) containing the S31N substitution indicates that the
mutation opens the channel allowing protons to enter.
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Figure 1-6 The Family Paramyxoviridae
The Paramyxoviridae family is subdivided into four subfamilies and 13 genera. Representative
members of each genus are represented in the dark gray boxes.
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Figure 1-7 Mumps virus Outbreaks
Reported mumps virus outbreaks in the United States from 1968 to 2019. The mumps vaccine
was introduced in 1968. Data as of October 11, 2019. Adapted from Morbidity and Mortality
Weekly Report (MMWR), Notifiable Diseases and Mortality Tables
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2.1

Abstract
The RNA polymerase of influenza virus consists of three subunits: PA, PB1 and PB2. It

uses a unique ‘cap-snatching’ mechanism for the transcription of viral mRNAs. The cap-binding
domain of the PB2 subunit (PB2cap) in the viral polymerase binds the cap of a host pre-mRNA
molecule, while the endonuclease of the PA subunit cleaves the RNA 10–13 nucleotides
downstream from the cap. The capped RNA fragment is then used as the primer for viral mRNA
transcription. The structure of PB2cap from influenza virus H1N1 A/California/ 07/2009 and of
its complex with the cap analog m7GTP were solved at high resolution. Structural changes are
observed in the cap-binding site of this new pandemic influenza virus strain, especially the
hydrophobic interactions between the ligand and the target protein. m7GTP binds deeper in the
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pocket than some other virus strains, much deeper than the host cap-binding proteins. Analysis of
the new H1N1 structures and comparisons with other structures provide new insights into the
design of small-molecule inhibitors that will be effective against multiple strains of both type A
and type B influenza viruses.
2.2

Introduction
Influenza virus causes seasonal epidemics that affect the health of millions of people

every year (41). Occasionally, a new pandemic strain emerges that can circulate the world in a
short period of time, such as the pandemic strain of H1N1 influenza A virus in 2009 (pH1N1
2009; (42)). Since influenza virus mutates rapidly and new strains emerge frequently through the
reassortment of viral strains originating from different hosts, new pandemic strains are expected.
Control of influenza virus is therefore a major public health task. In addition to vaccines,
antiviral drugs are a cost-effective means of controlling the spread of the virus. These drugs
usually have a broad spectrum of activities against multiple influenza virus strains and can be
stored on a relatively long term in strategic sites for rapid responses when new virus strains
emerge. However, resistant strains of influenza virus have regularly been identified (43).
Frequently prescribed anti-influenza drugs such as oseltamivir and zanamivir that are on the
market today primarily target one viral protein: influenza virus neuraminidase. Furthermore, the
Centers for Disease Control and Protection (CDC) report that high levels of resistance to the
adamantanes (amantadine and rimantadine) persist among the influenza A viruses currently
circulating. Adamatanes are ineffective against influenza B viruses. Consequently, it is desirable
to have a panel of antiviral drugs that target other viral proteins.
Influenza virus has a unique mechanism for its viral transcription (44). The viral RNAdependent RNA polymerase (vRdRp) of influenza virus has three virus encoded subunits: PA,
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PB1 and PB2. The vRdRp does not synthesize the cap of viral mRNAs; instead, it uses a primer
dependent mechanism for stealing a cap from the host pre-mRNA. The PB2 cap-binding domain
(PB2cap) is responsible for binding the 5’-cap on host pre-mRNAs; the PA endonuclease then
cleaves the snatched pre-mRNA 10–13 nucleotides downstream of the cap. The resulting
oligonucleotide is used as a primer to initiate polymerization by the PB1 subunit. The crystal
structure and functions of PB2cap have been carefully studied (19, 45, 46). The m7GTP binding
site consists of a hydrophobic side chain (residue His357 in influenza A virus or Trp359 in
influenza B virus) and a cluster of four aromatic residues (Figure 2-1A). The purine moiety is
sandwiched between the two hydrophobic side chains (His357 and Phe404). In addition, two
hydrogen bonds are formed by the purine moiety to the side chains of Glu361 and Lys376,
respectively. The ribose and the triphosphate may interact with PB2cap as well, but their
contribution to m7GTP binding appears to be less critical (45). It has been shown that the
structure of PB2cap is different from the cap-binding domains of other proteins, including human
proteins, and that the cap-binding site of PB2cap is conserved among different strains of
influenza virus (21). For instance, the cap moiety is sandwiched between a His residue and a
cluster of hydrophobic residues (Phe) in a deep pocket in PB2cap of influenza A virus. In the
human cap-binding protein, however, it is sandwiched between two Tyr residues and its
phosphate moiety is buried inside the binding site. PB2cap is therefore a viable target for broadspectrum antiviral agents against influenza virus (47).
The structures of inhibitors in complex with PB2cap have previously been reported (47,
48). A series of m7GTP derivatives have been synthesized with modifications at the N-2, N-7
and N-9 positions of the guanine moiety (47). The compounds that showed good activities in
blocking m7GTP binding mostly have a methyl group at the N-7 position, indicating a limited
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space for accommodating large groups at this position. The main modification that yielded good
inhibitory activities is at the N-9 position, where an aromatic moiety was added to replace the
pyranose in the cap structure. This aromatic moiety shows hydrophobic interactions with the side
chain of Phe323 (47). Recently, a new structure showed that a cyclohexyl carboxylic acid
analogue (named VX-787) binds in the cap-binding site with the azaindole moiety replacing the
7-methylguanidine (Figure 2-1B). The azaindole moiety recapitulates both the hydrophobic
interactions and hydrogen bonds of the purine moiety in the cap. In addition, the cyclohexyl
carboxylic group is coupled to azaindole via fluoropyrimidine. The cyclohexyl group provides
more hydrophobic interactions with the cluster of four aromatic residues. The carboxyl group
may form hydrogen bonds to two ordered water molecules. VX-787 reportedly has a strong
potency to inhibit a number of influenza A virus strains (48), but showed negligible activity
against influenza B virus (49). To explore the potential of designing a potent inhibitor that is
effective against multiple strains of both type A and type B influenza viruses, we solved the
crystal structures of PB2cap from pH1N1 A/California/07/2009 and its complex with m7GTP at
resolutions of 1.54 and 1.40 A, respectively. By comparing with different structures, we show
that the cap-binding site has a measurable flexibility to accommodate a compound that fits in the
hydrophobic pocket. The hydrogen bonds to the side chains of Glu361 and Lys376 should be
established because the inhibitor needs to displace a few ordered water molecules that interact
with these side chains. It is also necessary to establish a hydrogen bond to the side chain of
Arg334 in influenza B virus (Arg332 in influenza A virus) if the same inhibitor is to also bind
influenza B virus PB2cap (50).
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2.3
2.3.1

Materials and methods
Protein expression and purification
The DNA coding sequence for PB2cap from A/California/07/2009 H1N1 (CA09-

PB2cap) was inserted into pET-28a vector between NdeI and XhoI sites to generate a His6-tag
fusion protein with a thrombin cleavage site. Protein expression was carried out in Escherichia
coli BL21 (DE3) cells and expression was induced with 0.5 mM isopropyl β-D-1thiogalactopyranoside (IPTG) at 18C for 18 h. The recombinant protein was purified using a
nickel-affinity column (Ni2+-charged HiTrap chelating HP column from GE Healthcare). The
His6 tag was removed by incubation with thrombin protease for 4 h at 25C and the sample was
applied onto an Ni2+-charged HiTrap column again to remove uncleaved protein. The protein
was further purified by gel-filtration chromatography using a Superdex 75 column (GE
Healthcare) previously equilibrated with 10 mM Tris pH 8.0, 200 mM NaCl. The fractions
corresponding to the PB2cap protein were pooled and concentrated to 4–10 mg ml-1 for
crystallization. The expression vector for the PB2cap truncation mutant was generated using a
QuikChange kit (Agilent Technologies, California, USA) and the protein was purified following
the same procedure as used for native PB2cap.
2.3.2

Crystallization and structure analyses
The native and mutant PB2cap proteins were subjected to crystal screens (Index, Natrix,

PEG/Ion, Crystal Screen and Crystal Screen 2; Hampton Research, California, USA). After
optimization, crystals were grown by vapor diffusion with a hanging drop consisting of 10 mg
ml-1 native PB2cap protein mixed with a reservoir solution composed of 0.2 M magnesium
nitrate 0.1 M HEPES pH 8.0, 20%(w/v) PEG 3350 and a hanging drop consisting of 4 mg ml-1
mutant PB2cap protein mixed with a reservoir solution composed of 0.1 M bis-tris pH 6.5,
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15%(w/v) PEG 3350 at 20C. Cocrystallization was carried out by adding 0.2 mM m7 GTP to
the PB2cap solution and concentrating it to a final protein concentration of 4 mg ml-1 . The
cocrystals were grown under the same condition as used for the protein without m7GTP.
Protein crystals were transferred to a solution of mother liquor containing 20% glycerol
and were flash-cooled in liquid nitrogen. X-ray diffraction data were collected at Shanghai
Synchrotron Radiation Facility, China and SER-CAT at the Advanced Photon Source, USA.
Data processing was carried out with the HKL-2000 program suite. Molecular replacement was
performed with MOLREP using the coordinates of PDB entry 4enf (45) as the search model. The
structure of the mutant PB2cap was solved with the native structure following the same protocol.
Structural refinement was carried out with REFMAC5. MOLREP and REFMAC5 are part of the
CCP4 crystallographic package (51). X-ray crystallographic analyses are summarized in Table 1.
The coordinates of the reported structures were downloaded from the RCSB PDB. Structure
superposition and figure preparation were carried out using PyMOL (v.1.3; Schrödinger).
2.4
2.4.1

Results and discussion
The cap-binding site in PB2 of A/California/07/2009
The deeper end of the cap-binding site contains two critical residues: Glu361 and Lys376.

The side chains of these two residues form hydrogen bonds to the guanine moiety when the cap
binds. The side chain of Glu361 has a stable conformation, whereas that of Lys376 may assume
two different conformations (Figure 2-2A), one of which is suitable for forming the hydrogen
bond to the guanine moiety. There are also two important residues with aromatic side chains:
His357 and Phe404. These side chains sandwich the guanine moiety by π-π stacking interactions.
The side chain of His357 appears to rotate when the cap-binding site is empty (Figure 2-2B).
The orientation of the His357 side chain is different in A/California/07/2009 (H1N1) PB2cap
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compared with that in A/PR/8/34 (H1N1) PB2cap (Figure 2-2B). Next, the side chain of Phe323
makes hydrophobic interactions with the pyranose in the cap. Moreover, the side chain of
Lys339 is in a position to form a hydrogen bond to the 2’-OH of the pyranose, but it rotates away
when the cap-binding site is empty. Further out, the side chain of His432 may be involved in
charge interactions with the α-phosphate group in the cap, but its orientation is quite flexible.
The side chain of Asn429 is also in position to form a hydrogen bond to the α-phosphate group,
but it shows two orientations when the cap-binding site is empty.
There is an ordered water molecule that forms a hydrogen bond to the carbonyl group of
Phe404 (Figure 2-2A). This water molecule is displaced when the cap binds. A thiocyanate
group from the crystallization solution is modeled in a pocket lined by the side chains of Gln406
and Met431. In the structure of A/PR/8/34 PB2cap, a nitrate group from the crystallization buffer
is modeled in a nearby position. These observations suggest that there is a large space at this
location.
The most flexible regions are located in the large loops (Figure 2-2C). However, the
main-chain conformation near the cap-binding site also showed some flexibility. The major
differences are in the region from Thr333 to Lys339 and the region from Ala413 to Lys440
(Figure 2-2D), Thr333 is at the end of a β-strand and the polypeptide makes a sharp turn into the
next β-strand ending at Lys340. In A/PR/8/34 PB2cap, this region opens more widely so that the
side chain of Lys339 is no longer in a position to interact with the cap. Ala413 is at the start of
an α-helix, followed by a large flexible loop that ends at Lys440. This loop has a large influence
in crystallization. In the native PB2cap of A/California/07/2009 the side chain of Arg423 in the
loop occupies the cap-binding site, bridging strong interactions between two molecules in
the asymmetric unit. Attempts to soak m7GTP into the crystal or to cocrystallize with PB2cap of

33
A/California/07/2009 both failed. Since the Arg432 loop blocks the cap-binding site, we
therefore replaced residues Val421–Arg427 with a GSG linker to cut the loop short. The
shortened loop resulted in the loss of one turn in the α-helix. On the other hand, this helix has
one extra turn in the PB2cap of A/PR/8/34, leading to a different conformation of the following
loop. Overall, the cap-binding site in PB2cap showed considerable flexibility observed as
alternative side-chain orientations of the active-site residues and an alternative conformation of
the secondary-structure elements near the cap-binding site. These factors should be taken into
account when an inhibitor is designed to tightly bind the active site in PB2cap of all influenza
virus strains.
2.4.2

Interactions between m7GTP and the cap-binding site
As mentioned above, efforts to soak m7GTP into the crystal of the native PB2cap of

A/California/07/2009 were unsuccessful. When cocrystallization was attempted, the crystals
obtained did not contain m7GTP. We therefore carried out mutagenesis to shorten the loop that
occupies the cap-binding site of the neighboring molecule in the asymmetric unit. The mutant
PB2cap was subjected to crystal screens, and protein crystals were grown using 0.1M bis-tris pH
6.5, 15%(w/v) PEG 3350 as the reservoir solution. However, the crystals dissolved when soaked
in mother liquor containing 1mM m7GTP, indicating that a large conformational change was
induced by cap binding. Cocrystals of m7GTP were grown with the mutant PB2cap using the
same reservoir solution. Comparisons between the native and the complex structures revealed the
conformational changes when m7GTP binds to the cap-binding site (Figure 2-3A. All structures
used in the comparisons have been determined at 1.5 Å resolution or better. The truncated
mutant PB2cap has essentially the same structure as the native PB2cap (r.m.s.d. of 0.379 Å for
905 aligned atoms), except that the side chain of His357 has a different orientation, indicating a
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very flexible conformation for this side chain. The truncated mutant PB2cap was not included in
the comparisons.
In the complex of m7GTP with the mutant PB2cap, it appears that the main chain around
Glu361 has moved away by about 0.6 Å to allow the formation of proper hydrogen bonds
between the side chain of Glu361 and the guanine moiety (Figure 2-3A). The distances of the
Glu361 carboxyl O atoms to N1 and NH2 at position 2 of the guanine moiety are now 2.7 and
2.9 Å, respectively. At the same time, the side chain of Lys376 assumed one conformation
instead of the two possible conformations found in the native PB2cap in order to form a proper
hydrogen bond to the carbonyl O atom at position 6. The ordered water molecule at the carbonyl
group of Phe404 was clearly displaced. More visibly, the side chain of His357 was rotated so
that it could make the most π–π stacking with the guanine moiety (Figure 2-3A). The side chain
of Phe404 is usually identified as contributing to π–π stacking on the other side of the guanine
moiety (21). However, the side chain of Phe323 is also in an appropriate position to form π–
π stacking with the guanine moiety. Moreover, the side chain of Phe363 is within a suitable
distance to make a T-shaped interaction with the guanine moiety. It is likely that the three
aromatic side chains jointly make strong hydrophobic interactions with the guanine moiety. The
methyl group at position 7 is located in a hydrophobic pocket formed by Phe404, Met431 and
part of the Gln406 side chain. The side chain of Met431 actually retracted so that the distance
between the two methyl groups changes from 3.0 Å (closest distance in van der Waals
interactions) to 4.5 Å.
The 2′-OH group forms hydrogen bonds to the side chains of Lys339 and His357 in
PB2cap of A/California/07/2009. The pyranose ring is roughly orthogonal to the guanine moiety.
This ring may have some degree of hydrophobic interaction with the side chain of Phe323, but
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their orientation is not parallel and the distance is long. It may not make a significant
contribution to cap binding. The α-phosphate group clearly makes salt-bridge and hydrogenbond interactions with the side chains of His432 and Asn429. His432 assumes two
conformations in the interactions, one of which overlaps with one of the two conformations in
the native PB2cap. The Asn429 side chain assumes only one conformation that overlaps with
one of the two conformations in the native PB2cap. The β-phosphate group could make a salt
bridge with the side chain of Lys339, which moved from a distance of 2.2 to 2.7 Å. However, the
conformation of the β-phosphate group as well as that of the γ-phosphate group change
dramatically in different PB2cap structures. How the phosphate groups interact with PB2cap
may only become clearer when the cap is placed in the context of the full-length viral
polymerase complex. It is clear, however, that a positively charged residue, Lys or Arg, is
conserved at position 339. Its side chain is highly likely to form a salt bridge to one of the
phosphate groups in the cap.
The cap binding is also compared with PB2cap of A/Duck/Shantou/4610/2003 (H5N1;
Pautus et al., 2013; Figure 2-3B) and A/Hong Kong/1/68 (H3N2; Liu et al., 2013; Figure 2-3C).
In PB2cap of H5N1, m7GTP is moved outwards from the cap-binding site by 0.5 Å.
Accordingly, the side chain of His357 also moves to maintain the π–π stacking, accompanied by
movement of the main chain. The pyranose ring is rotated by about 22.6° so that it has less
inclination relative to the guanine moiety. As a result, the 2′-OH group no longer forms a
hydrogen bond to the side chain of His357. The side chain of Lys339, on the other hand, still
forms a hydrogen bond to the 2′-OH group, but it has to move towards the OH group
accompanied by movement of the main chain. The conformation of all three phosphate groups is
different in the three structures, and no consensus interactions may be discerned. In PB2cap of
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H3N2 all interactions are similar to those found in A/California/07/2009, except that the side
chain of Phe323 is shifted owing to movement of the main chain. Since Phe323 is close to the
terminus of PB2cap, the crystal contacts may have an effect on its side-chain conformation.
2.4.3

Comparisons with PB2cap inhibitors
The structures of two classes of inhibitors in complex with PB2cap are available (Figure

2-4). The complex of a representative compound (8f) with PB2cap of H5N1
A/duck/Shantou/4610/2003 PB2cap is used for comparison with the first class of inhibitors.
Compound 8f is a derivative of m7-guanine and showed modest inhibition of cap binding to
PB2cap (47). The structure shows that the guanine moiety of compound 8f retains essentially the
same interactions as those in m7GTP (Figure 2-4A). The phenyl group coupled to the guanine
moiety should make some hydrophobic interactions with the side chain of Phe303, but is not
close enough for π–π stacking. The hydroxyl group on the phenyl ring may form a hydrogen
bond to the main chain via a water molecule. This compound has only limited interactions with
PB2cap, consistent with its modest inhibitory activity.
On the other hand, the cyclohexyl carboxylic acid analogue VX-787 is a potent inhibitor
(48). In its complex with PB2cap of A/Victoria/3/1975 H3N2 (Figure 2-4B), the N atom at
position 4 of the azaindole moiety forms a hydrogen bond to the side chain of Glu361 and the N
atom at position 9 forms a hydrogen bond to the side chain of Lys376. More importantly, the
azaindole pyrimidinyl moiety is in a perfect position to make π–π stacking interactions with the
side chains of Phe323 and Phe404 simultaneously. Furthermore, the bicyclooctane coupled to the
pyrimidinyl moiety perfectly occupies the hydrophobic pocket formed by the side chains of
Phe325 and Met431. Finally, the carboxyl group linked to the bicyclooctane forms a salt bridge
with the side chain of Arg355 and hydrogen bonds to the side chains of His357 and
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Gln406 via water molecules. The side chain of Lys339 (Arg339) is close by. Its side chain could
also form a salt bridge with the carboxyl group in different influenza A virus strains. VX-787
capitalizes on all available interactions with PB2cap and showed potent inhibitory activities
against a number of influenza A virus strains (48).
2.4.4

Differences from PB2cap of influenza B virus
VX-787 is not active against influenza B virus (49). Since influenza B virus is also a

serious health threat, it is more desirable to have an inhibitor that is effective against both
influenza A and B viruses. Comparison of the VX-787 complex structure with the GDP complex
of influenza B PB2cap (50) may suggest why VX-787 does not effectively inhibit influenza B
viruses (Figure 2-5A). The guanine moiety in PB2cap of influenza B virus B/Jiangxi/BV/2006 is
rotated 180° relative to that in PB2cap of influenza A virus (Figure 2-5B). As a result, the N
atom at position 1 and the amino group linked to position 2 still form hydrogen bonds to the side
chain of Glu361, but in a reversed orientation. The carbonyl at position 6 now forms a hydrogen
bond to the side chain of Arg332 (Arg334 in influenza B virus) instead of that of Lys376. His357
is replaced by Trp, which makes more π–π stacking interactions with the guanine moiety.
However, π–π stacking interactions on the other side are only retained for the side chain of
Phe404. Phe323 is replaced by Gln, which can no longer provide π–π stacking. Moreover,
His432 is replaced by Tyr, which has a bulkier side chain that provides steric hindrance to
bicyclooctane. It seems that many of the favorable interactions between VX-787 and PB2cap of
influenza A virus do not exist in PB2cap of influenza B virus, and more importantly some
residues in PB2cap of influenza B virus could potentially pose steric hindrance to VX-787, such
as Tyr432. The characteristics of both cap-binding sites need to be considered simultaneously if
one inhibitor is to be designed against both influenza A and B viruses.
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2.4.5

Comparisons with human cap-binding proteins
Binding of an inhibitor to host cap-binding proteins needs to be avoided in order to

design specific inhibitors of PB2cap. The structures of a cap-specific mRNA methyltransferase
(52) and the translation initiation factor eIF4E (53) were used as examples (Figure 2-6). In the
methyltransferase, the carbonyl O atom in the guanine moiety forms a hydrogen bond to the
main-chain amide N atom of Trp102 (Figure 2-6A). The side chain of Glu103 forms two
hydrogen bonds to the N atom at position 1 and the amino group linked to position 2,
respectively. There are π–π stacking interactions made by Trp56 and Trp102 on each side of the
guanine moiety. The methyl group linked to position 7 does not seem to be in a pocket but is
near the side chain of Trp166. There seems to be no direct interactions between the protein and
the pyranose ring. On the other hand, strong interactions are present between the α- and βphosphate groups and the side chain of Arg157, and between the β- and γ-phosphate groups and
the side chain of Lys162.
In eIF4E, the side chain of Asp207 forms a hydrogen bond to the N atom at position 1
and that of Asn374 forms a hydrogen bond to the amino group linked to position 2 (Figure
2-6B). There are no aromatic π–π stacking interactions with the guanine moiety, but the side
chain of Glu373 shows an anion–aromatic stacking interaction with the guanine moiety. Again,
there is no direction interaction with the pyranose ring. Charge or hydrogen-bond interactions are
present between the β-phosphate group and the side chain of Asn439 and between the α- and γphosphate groups and the side chain of Arg218.
Overall, the interactions between the cap and the host proteins include those with the
guanine and preferentially the phosphate groups. The binding site is not as deep as that in
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PB2cap. There is no interaction with the pyranose ring, which seems to serve only as a linker
between the guanine moiety and the triphosphate.
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Figure 2-1 The cap-binding site in PB2cap
(a) A/California/07/2009 PB2cap bound to m7GTP (PDB entry 5eg7 ), (b) A/Victoria/3/1975
PB2cap bound to VX-787 (PDB entry 4p1u ; Clark et al., 2014). The residues are labeled
according to the numbering of A/California/07/2009 PB2cap in this and the following figures.
Each ligand in the PB2cap binding site is also labeled.
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Table 2-1 Data-collection and refinement statistics
Values in parentheses are for the highest resolution shell

5eg8

m7GTP-mutant
CA09-PB2cap
5eg7

Mutant CA09PB2cap
5eg9

P3121

P43212

P1211

54.61
54.61
196.49
90
90
120
2

45.26
45.26
156.40
90
90
90
1

37.13
109.01
39.66
90
90.54
90
2

0.9795
15-1.54 (1.591.54)
7.0 (21.4)
57.9 (14.2)
0.997 (0.992)
97.2 (96.9)
15.1 (16.7)

1.0000
25-1.40 (1.42-1.40)
7.1 (61.1)
33.2 (1.8)
0.912 (0.581)
99.8 (97.0)
10.4 (4.0)

1.0000
50-2.30(2.342.30)
7.1(19.4)
21.2(6.2)
0.893 (0.906)
87.7(92.6)
1.8(1.7)

14.63-1.54
47547
12.2/17.7
24.9

25-1.40
31406
12.4/16.9
16.1

19.83-2.30
11663
19.0/25.6
29.3

0.019
1.93

0.020
2.35

0.014
1.65

97.5
2.2
0.3

98.1
1.9
-

96.8
2.6
0.6

Protein

CA09-PB2cap

PDB code
Data Collection
Space group
Unit-cell parameters
a (Å)
b (Å)
c (Å)
α (°)
β (°)
γ (°)
Molecules in asymmetric
unit
Wavelength (Å)
Resolution (Å)
Rmerge† (%)
〈I/σ(I)〉
CC1/2
Completeness (%)
Multiplicity
Refinement
Resolution (Å)
No. reflections
Rwork/Rfree ‡ (%)
Average B factor (Å2)
R.m.s. deviations
Bond lengths (Å)
Bond angles (°)
Ramachandran plot (%)
Favored region
Allowed region
Outlier region
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Figure 2-2 Structure of Influenza A cap binding site
(a) The cap-binding site in PB2cap of A/California/07/2009 (PDB entry 5eg8 ); 11 residues
(labeled) and one water molecule (sphere) are shown. Lys376, Asn429 and His432 are
represented by two alternative side-chain conformations. (b) Comparisons of the cap-binding
site in A/California/07/2009 PB2cap (gray) and A/PR/8/34 PB2cap (PDB entry 4enf ; pink; Liu
et al., 2013). Residues Lys376, Asn429 and His432 in A/PR/8/34 PB2cap do not show alternative
conformations. (c) A main-chain diagram of A/California/07/2009 PB2cap; the B factor is used
to puff the trace (PyMOL). The N- and C-termini are labeled N and C, respectively. The location
of the cap-binding site is indicated. (d) Comparison of three PB2cap structures: native (gray),
mutant (green) and A/PR/8/34 (pink); residue Lys339 is labeled. The N- and C-termini are
labeled N and C, respectively. The location of the cap-binding site is indicated.
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Figure 2-3 Comparing bound and unbound PB2cap
(a) Comparison of the native (gray) and m7GTP-bound (green) cap-binding site in
A/California/07/2009 PB2cap. Lys376 and Asn425 showed only one conformation in the
complex, whereas His357, Met431 and His432 have alternative conformations in the complex.
(b) Comparison of the cap-binding site with m7GTP bound in A/California/07/2009 PB2cap
(green) and A/Duck/Shantou/4610/2003 (H5N1) PB2cap (PDB entry 4cb4 ; yellow; Pautus et
al., 2013). These two structures have the closest superposition. (c) Comparison of the capbinding site in m7GTP-bound A/California/07/2009 PB2cap (green) and A/Hong Kong/1/68
PB2cap (H3N2; PDB entry 4eqk ; blue; Liu et al., 2013). The two structures are also
superimpose well.
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Figure 2-4 Comparison of the PB2cap cap-binding site.
(a) A/California/07/2009 PB2cap bound to m7GTP (green) and A/Duck/Shantou/4610/2003
PB2cap bound to compound 8f (PDB entry 4cb5 ; orange; Pautus et al., 2013). `Ligands'
indicate the locations of m7GTP and 8f. (b) A/California/07/2009 PB2cap bound to m7GTP
(green) and A/Victoria/3/1975 PB2cap bound to VX-787 (PDB entry 4p1u ; orange; Clark et
al., 2014).
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Figure 2-5 Comparing Influenza A and B cap binding
(a) Comparison of the GDP-bound cap-binding site in B/Jiangxi/BV/2006 PB2cap (PDB entry
4q46 ; magenta; Liu et al., 2015) and the m7GTP-bound cap-binding site in
A/California/07/2009 PB2cap (green). Residues in B/Jiangxi/BV/2006 PB2cap are labeled in
purple if they are different from those in A/California/07/2009 PB2cap. `Ligands' indicates the
locations of GDP and m7GTP, respectively. (b) Comparison of the GDP-bound cap-binding site
in B/Jiangxi/BV/2006 PB2cap (PDB entry 4q46; magenta) and the VX-787-bound cap-binding
site in A/Victoria/3/1975 PB2cap (PDB entry 4p1u; orange; Clark et al., 2014). Residues in
B/Jiangxi/BV/2006 PB2cap are labeled in purple if they are different from those in
A/California/07/2009 PB2cap. `Ligands' indicates the locations of GDP and VX-787,
respectively.
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Figure 2-6 Human cap binding proteins
The cap-binding site (a) in the cap-specific mRNA methyltransferase bound to m7GTP (PDB
entry 4n49 ; Smietanski et al., 2014) and (b) in the translation initiation factor eIF4E bound to
m7GTP (PDB entry 4tqb ; Papodopolous et al., 2014).
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3.1

Abstract
In a negative-strand RNA virus, the genomic RNA is sequestered inside the nucleocapsid

when the viral RNA-dependent RNA polymerase uses it as the template for viral RNA synthesis.
It must require a conformational change in the nucleocapsid protein (N) to make the RNA
accessible to the viral polymerase during this process. The structure of an empty mumps virus
(MuV) nucleocapsid-like particle was determined to 10.4-Å resolution by cryo-electron
microscopy (cryo-EM) image reconstruction. By modeling the crystal structure of parainfluenza
virus 5 into the density, it was shown that the α-helix close to the RNA became flexible when
RNA was removed. Point mutations in this helix resulted in loss of polymerase activities. Since
the core of N is rigid in the nucleocapsid, we suggest that interactions between this region of the
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mumps virus N and its polymerase, instead of large N domain rotations, lead to exposure of the
sequestered genomic RNA.
3.1.1

Importance
Mumps virus (MuV) infection may cause serious diseases, including hearing loss,

orchitis, oophoritis, mastitis, and pancreatitis. MuV is a negative-strand RNA virus, similar to
rabies virus or Ebola virus, that has a unique mechanism of viral RNA synthesis. They all make
their own RNA-dependent RNA polymerase (RdRp). The viral RdRp uses the genomic RNA
inside the viral nucleocapsid as the template to synthesize viral RNAs. Since the template RNA
is always sequestered in the nucleocapsid, the viral RdRp must find a way to open it up in order
to gain access to the covered template. Our work reported here shows that a helix structural
element in the MuV nucleocapsid protein becomes open when the sequestered RNA is released.
The amino acids related to this helix are required for RdRp to synthesize viral RNA. We propose
that the viral RdRp pulls this helix open to release the genomic RNA.
3.2

Introduction
Many negative-strand RNA viruses (NSVs) are important human pathogens that frequently

cause outbreaks. The Ebola virus outbreak in West Africa in 2014 (54) and the pandemic
influenza A virus H1N1 outbreak in 2009 (55) are two recent examples. Some pathogens appear
to reemerge in spite of available vaccines, such as mumps virus and measles virus (56–58).
Effective controls are needed to combat these pathogens. In order to develop more effective
countermeasures, the mechanism of NSV replication should be better understood. One of the
unique features in NSVs is that the genomic RNA is sequestered in the nucleocapsid (59).
During transcription and replication, the viral RNA-dependent RNA polymerase (vRdRp) must
be able to gain access to the sequestered genomic RNA in order to use it as the template.
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For Rhabdoviridae and Paramyxoviridae, the virus encodes a single nucleocapsid protein (N)
that polymerizes as a linear capsid to encapsidate the genomic RNA (60). The viral polymerase
complex consists of the large protein (L) and the phosphoprotein (P).
The structure of the nucleocapsid or a nucleocapsid-like particle has been solved for
several members of Rhabdoviridae and Paramyxoviridae by X-ray crystallography or cryoelectron microscopy (cryo-EM) three-dimensional (3D) reconstruction (4, 61–64). The common
features among various structures are that the N protein has an N-terminal domain and Cterminal domain in its core, composed mostly of α-helices. When the N subunits assemble into a
polymeric capsid, they are aligned in parallel in a linear fashion (65). There are extensive sideby-side interactions between the neighboring domains and domain swaps of extended loops and
long termini. The genomic RNA is encapsidated in a cavity formed between the two core
domains. Most of the RNA bases are stacked, some of which face the exterior and some the
interior of the N protein core. The tight assembly of the nucleocapsid clearly suggests that
vRdRp must open the N protein core in order to unveil the genomic RNA. How this action is
carried out remains to be discovered. The interaction of the polymerase cofactor P with the
nucleocapsid may provide some insights on this subject. The C-terminal domain of vesicular
stomatitis virus (VSV) P protein binds between the extended loops in the C-terminal domains of
two neighboring parallel N subunits (66). Since the P protein is a part of the vRdRp complex,
this binding will place the polymerase in a close proximity to the “gate” covering the genomic
RNA. However, the binding of VSV P protein does not seem to induce a significant
conformational change in the N protein. It has also been shown that an N-terminal fragment of
VSV P protein binds in a truncated empty capsid with an α-helix that sits in the RNA cavity and
an extended N-terminal polypeptide that occupies the space vacated by the deletion of the N-
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terminal arm of VSV N protein (67). However, this fragment of the VSV P protein could not
bind the nucleocapsid or release the genomic RNA. It seems that the P protein can bind the
nucleocapsid but is not able to unveil the genomic RNA alone.
Mumps virus (MuV) and parainfluenza virus 5 (PIV5) are members of Rubulavirus, a
genus of Paramyxoviridae. The nucleocapsids of these two viruses tend to coil into a helical
structure even when packaged inside the virion. There are on average 13 subunits per turn in the
helical structure (68). A unique characteristic of viruses like rubulaviruses is that the length of
the RNA genome should be an integer with 6 as a divisor, the so called “rule of six,” suggesting
that the single N subunit repeat corresponds to a repeat of 6 nucleotides in the encapsidated
genomic RNA (69). In previous studies, it was shown that the MuV N protein forms a ring of 13
subunits when it is coexpressed with the P protein in Escherichia coli (68). A 78-nucleotide
piece of RNA presumably having random sequences was found encapsidated in the ring
structure. The packaged RNA could be easily removed by high salt concentrations, low pH, or
RNase A, in contrast to the case for VSV nucleocapsid. The C-terminal domain of MuV P
protein binds between the two neighboring N subunits in the nucleocapsid, having a similar
stoichiometry as VSV P protein. However, the binding site for MuV P protein is closer to the Nterminal domain of its N protein, whereas the binding site for VSV P protein is closer to the Cterminal domain of its N protein. Moreover, the N-terminal domain of MuV P protein also binds
and uncoils the nucleocapsid (40). The P N-terminal domain alone can enhance viral RNA
synthesis, which has not been reported for other NSVs. Recently, the crystal structure of a
truncated PIV5 N-RNA ring was reported (64). The N protein of PIV5 has the same typical twodomain fold as the N protein of other NSVs and is most homologous to that of Nipah virus (NiV)
(70). In each N subunit, six nucleotides were covered, with three stacked bases facing the interior

51
and three facing the exterior of the N protein. By comparing the structure of the PIV5 N protein
with that of the monomeric NiV N protein, which seems to have a more open conformation
between the two N domains, it was hypothesized that the C-terminal domain of PIV5 N protein
needs to rotate out in order for the viral polymerase complex to unveil the sequestered RNA (64).
In this report, we show that a loop-helix α7 region in MuV N protein is the most flexible region
when the sequestered RNA is released. Mutation of a few residues in this region also diminished
or reduced viral RNA synthesis. These data suggest an alternative mechanism, namely, that the
viral polymerase complex needs only to induce a local conformational change of the loop-helix
α7 to unveil the sequestered genomic RNA and does not need to bend open a very stable N
protein core.
3.3

Materials and methods

3.3.1

Expression and purification of recombinant MuV N protein

All plasmid sequences were based on MuV isolated during an outbreak in Iowa in 2006
(GenBank accession no. JN012242). The coding sequence corresponding to residues 1 to 379 of
MuV N protein was coexpressed with the His tagged P protein using plasmid pET28b. After
purification of the protein complex with an Ni column, the N379 protein was purified by ionexchange chromatography (HiTrap Q HP; GE Healthcare). The purified N 379 protein sample that
contains random RNA was dialyzed against 20 mM HEPES, pH 7.5. The packaged RNA was
removed from the purified N379 protein by treatment with 1 mg/ml of RNase A overnight at room
temperature.
3.3.2

Cryo-EM structure of the empty MuV N assembly.

Cryo-EM images of the N379-RNA complex and the empty N379 complex were collected at
the National Resource for Automated Molecular Microscopy (NRAMM) in the Scripps Research
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Institute. Data were acquired on a Tecnai F20 electron microscope operating at 200 kV, with a
Gatan 4kx4k charge-coupled device (CCD) camera to record the images at a pixel size of 1.21 Å.
A total of 191 images were included in the final data set for the empty N 379 complex. Segments
of the empty capsid helices were selected with helixboxer from the SPARX/EMAN2 package,
using 10% overlap between particles. Particles were aligned using a mask. Contrast transfer
function (CTF) corrections were performed with EMAN2. The IHRSR method was used to
refine the 3D reconstruction using a noisy cylinder of 220 Å in diameter as the initial model. The
initial parameters used for the helical refinement were from the cryo-EM structure of the
authentic nucleocapsid (40). The final structure was refined with 5,578 particles, and the
resolution was determined to be 10.4 Å using FSC = 0.5. The helical structural model was
constructed using PyMol (71) and PIV5 N coordinates from PDB code 4XJN. NiV N coordinates
were from PDB code 4CO6. Fitting of the model coordinates into the density was carried out
with Chimera (72). Segmentation and superposition of densities were also performed with
Chimera.
3.3.3

Minigenome assays.
The point mutations in the loop-helix α7 region of MuV N were generated by introducing

point mutations into the MuV N gene previously cloned into the pCAGGS expression vector
(73). Mutations were introduced by splicing by overlap extension (SOE) mutagenesis using
Phusion polymerase (Thermo Scientific), as previously described (74). All constructs were
confirmed by sequencing at Genewiz.
The minigenome assay was performed as previously described (74). In short, BSR-T7
cells (1 day, 60 to 80% confluent, 24-well plate) were transfected with pCAGGS-P (80 ng),
pCAGGS-L (500 ng), pT7-MG-RLuc (100 ng), and pFF-Luc (1 ng), along with various amounts
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of pCAGGS-N (wild type [wt], Tyr185Pro, Ala197Gln, or Gln200Arg at 25, 50, 100, or 200 ng)
using jetPRIME (Polyplus) according to the manufacturer's specifications. After 48 h, cells were
lysed and a dual-luciferase assay (Promega) was performed using a portion of the lysate.
Luminescence was measuring using a GloMax 96 microplate luminometer (Promega). The ratio
of Renilla to firefly luciferase was reported for 4 experimental replicates.
Expression levels of N were determined by Western blotting using a portion of the minigenome
lysate. All four experimental replicates were combined and mixed with 2× Laemmli sample
buffer (Bio-Rad) containing β-mercaptoethanol. Samples were heated at 95°C, resolved on 10%
mini-Protean TGX protein gels (Bio-Rad) by SDS-PAGE, and transferred to Amersham Hybond
LFP polyvinylidene difluoride (PVDF) membranes (GE Healthcare Life Sciences).
Immunoblotting was performed with an anti-N monoclonal antibody (MAb), followed by
incubation with a Cy3-conjugated goat anti-mouse IgG (Jackson ImmunoResearch). The blot
was visualized on a Typhoon FLA 7000 instrument (GE Healthcare Life Sciences), and
densitometry was performed using ImageQuant TL (GE Healthcare). Values were normalized to
wt N at 50 ng/well.
3.4
3.4.1

Results
Structure of a truncated empty capsid.
In a previous study, the MuV N protein was coexpressed with the P protein, and a ring of

13 subunits that packages random RNA inside was isolated (68). When the purified ring was
stored for a few weeks at 4°C, it was found that the N protein was truncated after residue 379
(N379) (75). The same truncation could be generated by trypsin treatment. Here, a vector was
constructed to coexpress N379 with the P protein that has a His6 tag at the N terminus. The N379-P
complex was purified using an Ni column, and the N379 protein was further purified with an ion-
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exchange column. N379 still forms a ring of 13 subunits with random RNA packaged. However,
the rings of N379-RNA can stack and transform into a nucleocapsid-like helical structure (Figure
3-1A). The random RNA sequence could be removed with RNase A, and long helical empty
capsids were formed by N379 (Figure 3-1B). The structure of the empty capsid formed by
N379 was determined to a 10.4-Å resolution by cryo-EM 3D image reconstruction (Figure 3-1C).
The diameter of the left-handed truncated empty capsid is about 218 Å, similar to that of the
authentic nucleocapsid purified from mumps virions (40). The pitch height, however, is much
lower, at about 49 Å (a rise of 3.7 Å per subunit), compared to 67 Å for the authentic
nucleocapsid. The rotation of one subunit to the next is 27° about the central axis, making 13.3
subunits per turn, compared to 12.7 subunits per turn in the authentic nucleocapsid. The crystal
structure of the PIV5 N-RNA ring complex contains only the fragment of N401 (64). Since the
sequence of MuV N379 is highly homologous to the sequence of N401, the coordinates of residues
3 to 379 without RNA from this crystal structure were used to construct an atomic model by
rotating a subunit by 27° counterclockwise about the central axis and downshifting by 3.7 Å. The
model as a rigid body fits our density map well (Figure 3-1D). The empty space between the Nand C-terminal domains of the N protein density is consistent with removal of RNA by RNase A
treatment. It appears that transition from a ring structure to a helical structure does not require
significant conformational changes in the subunits. In this model, no rotation was introduced in
either the N- or C-terminal domain of the N protein.
3.4.2

Comparison with the authentic nucleocapsid.
The structure of the truncated empty capsid was compared with that of the authentic

nucleocapsid determined at an 18-Å resolution (40). The density of the two structures was
segmented at about the 2σ contour level. As shown in Figure 3-2A, the two segments can be
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superimposed fairly well except for two regions. The authentic nucleocapsid has more density
between the N- and C-terminal domains, consistent with having genomic RNA encapsidated in
the nucleocapsid. As shown in Figure 3-2B, there is no density corresponding to the location of
RNA when the coordinates of PIV5 N are superimposed in the segment. There is also a piece of
extra density in the authentic nucleocapsid near the C-terminal end of N379. When the density of
an N379 segment is superimposed onto the helical structure of the authentic nucleocapsid (Figure
3-2C), this extra piece of density is involved in the contact between the successive turns. The
extra density seems to be responsible for increasing the pitch height of the authentic
nucleocapsid. Part of residues 380 to 549, missing from N379 (also known as the N-tail),
corresponds to this piece of density, but the size of the density is too small to account for all
residues. While some of the N-tail residues make contacts between the successive turns, the rest
of the N-tail is likely to point to the exterior of the helical structure, where it was shown to
interact with the nucleocapsid binding domain of the P protein (40).
3.4.3

How is the encapsidated genomic RNA unveiled by the viral polymerase?
As shown for a number of negative-strand RNA virus nucleocapsid-like structures, the

genomic RNA is sequestered in the nucleocapsid with some of the stacked nucleotide bases
facing the interior of the N protein (76). In order to use the sequestered genomic RNA as a
template for viral synthesis, a conformational change must be induced by the viral polymerase
complex to temporarily release the RNA from the N protein. It has been suggested that one of the
two N protein domains surrounding the genomic RNA can swing open so the template RNA
becomes accessible by vRdRp (64). The N structure from the PIV5 N401-RNA complex was
compared with that of a truncated N protein (N32–383) of NiV in complex with a fragment of the P
protein. There is no RNA in the NiV N32–383 structure. The comparison showed that the N- or C-
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terminal domain of the two N proteins can be superimposed separately. If the N-terminal
domains were superimposed, it would require a 20° rotation to bring the C-terminal domain of
PIV5 N to overlap that of NiV N. This observation was the basis for the hypothesis that the Cterminal domain of PIV5 N is the domain that rotates upon polymerase binding, not the Nterminal domain (64). To examine this hypothesis, the coordinates of PIV5 N and NiV N 32–
383

were superimposed onto the density of the truncated empty capsid of MuV. The PIV5 N

structure can be superimposed well without any conformational changes in the two domains. On
the other hand, only one of the two domains in NiV N32–383 may be properly superimposed in the
density each time. If the N-terminal domain is superimposed, the C-terminal domain of NiV N32–
383

will stick out of the density toward the interior of the helical empty capsid. If the C-terminal

domain is superimposed, the N-terminal domain of NiV N32–383 will be outside density.
However, the motion that may bring the N-terminal domain back into the density requires mostly
a rotation about the helical axis (Figure 3-3C). The two sets of coordinates were also mapped
based on the B factor, a factor that correlates with structural stability (Figure 3-3A and D). The
core of the PIV5 N-RNA complex has very low B factors, suggesting a high structural stability.
This will make it very hard to open either the C- or N-terminal domain because of the high
energy requirement. Similarly, the core of NiV N32–383 also has lower B factors. However, the
surface residues in the N-terminal domain NiV N32–383 have relatively higher B factors. This is
consistent with the fact that the truncated monomeric NiV N protein has neither neighboring
subunits nor RNA to stabilize it. It was also observed that when the RNA was removed from the
authentic nucleocapsid, the MuV empty capsid became more flexible (40). We noticed, however,
that residues in helix α7 and the prior loop of PIV5 N also have very high B factors comparable
to the residues in the N and C termini, among which residues 183 to 186 were actually
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disordered (Figure 3-3B). The homologous region in the NiV N has similar B factors and
disordered residues. When the coordinates of PIV5 N are superimposed with the structure of the
MuV truncated empty capsid, there is no density corresponding to the loop-helix α7 (Figure
3-2B). The same observation was made with superposition of the NiV N 32–383, in which there is
no corresponding density for the homologous loop-helix. We propose that the viral polymerase
complex is required only to open this loop-helix α7 region in order to gain access to the
sequestered RNA, instead of bending open a very stable protein core by rotating either the N- or
C-terminal domain.
3.4.4

Residues in the loop-helix α7 are critical.
We compared the sequence of the MuV N protein with that of the PIV5 N protein and

found that in the loop-helix α7, three residues are different between the two proteins: residues
Tyr185, Ala197, and Gln200 (Figure 3-3A). Since vRdRp of one virus could not work with
other nucleocapsids, we argue that changing these three amino acids of MuV to those of PIV5
would compromise viral RNA synthesis if they are required for vRdRp interactions with the N
protein. Three mutant N proteins were therefore generated, corresponding to the changes
Tyr185Pro, Ala197Gln, and Gln200Arg. The minigenome activity assay and Western blotting
for quantitating the expression of mutant MuV N proteins were carried out, and the results are
summarized in Figure 3-4. According to Western blot analysis, the mutant N proteins have
levels of expression similar to or even higher than that of the wt sequence (Figure 3-4A).
However, the minigenome activities using the mutant N proteins were significantly reduced
compared to that using the wt N protein (Figure 3-4B). Gln200Arg had almost no activity,
consistent with the fact that mutation from Gln to Arg represents a large side chain change from
a polar residue to a positively charged residue.
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3.5

Discussion
Transition of the MuV N-RNA complex to a helical structure suggests that the helical

nucleocapsid is a very stable structure. By changing to a helical structure, most of the lateral
interactions observed in the N-RNA ring are likely to be preserved, especially if the N subunit is
allowed to rotate itself. The interactions observed in the crystal structure of NSV N-RNA rings
are therefore valid for interpreting N subunit interactions in the authentic nucleocapsid. The
protein-protein contact between the neighboring N subunits is massive in the nucleocapsid,
provided by side-by-side interactions and domain swaps. Deletion of these interactions will
result in disassembly of the capsid and loss of RNA encapsidation (77). In the structure of empty
capsids shown here and reported previously (77), the same interactions are retained, suggesting
that release of sequestered RNA may not require global conformational changes in the N protein.
As shown in the PIV5 N-RNA structure, each C-terminal domain has an interface of 327 Å2 with
both sides and domain swapping of its C-terminal arm (residues 373 to 401) with another
neighboring N subunit. The interactions of the N-terminal domain are even more extensive (883
Å2). A global conformational change of either domain will cost a large amount of destabilization
energy. In addition, the integrity of the nucleocapsid must be restored when the viral polymerase
finishes RNA synthesis at the region where RNA is unveiled. It may not be reversible if large
conformational changes are induced in the N protein during viral RNA synthesis.
The conformation of the two domains in NiV N appears to be more open than that in the N
protein of respiratory syncytial virus (70). However, the two N domains may become more
closed in other NSV N proteins, such as bunyaviruses (78–81). The degree of openness of the
two domains may not necessarily be related to the mode of RNA encapsidation by the N protein
or the flexibility of the N protein core. If a hinge is present between the two N domains, it is
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likely that a more flexible linker is present in the N protein core. Based on the B factors, there is
no such flexible linker between the two domains in either PIV5 or NiV N. Moreover, the crystal
structure of a measles virus Ncore-P complex shows that the RNA-free monomeric N protein has
a more collapsed conformation than that in the nucleocapsid (82). The conformation of the RNAfree N protein is therefore not related to how the sequestered RNA is unveiled during viral RNA
synthesis.
An N-terminal fragment of NiV P could bind the RNA-free monometric truncated N32–383,
but no evidence supports that this fragment could bind the nucleocapsid (70). The P protein
functions as a chaperone to keep the N protein monomeric before nucleocapsid assembly. The
published structures showed that the N-terminal regions can bind at the sites that are involved in
stabilizing the nucleocapsid, such as interactions for domain swapping or RNA binding (70, 82).
Once the monomeric N subunit is incorporated in the nucleocapsid, the P protein must be
dissociated, and the interactions of the N subunits are established. There is no evidence to
suggest that the P protein can compete with such cooperative interactions. Our results showed
that the loop-helix α7 is the most flexible region when sequestered RNA is released. When RNA
is removed, this region becomes more flexible. Single-amino-acid mutations of the MuV N
sequence to those of the PIV5 N sequence significantly reduced the minigenome activity (Figure
3-4), reaffirming the involvement of this region in viral RNA synthesis. We suggest that specific
interactions of this MuV N region with the polymerase are required for unveiling the RNA for
viral RNA synthesis. These observations are consistent with the proposed mechanism that the
viral polymerase complex can unveil the sequestered RNA by inducing a local conformational
change of the loop-helix α7. The loop-helix α7 should be able to readily restore the structure of
the nucleocapsid after viral RNA synthesis because it is only a local conformational change.
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Figure 3-1 CryoEM Structure of N379
(A) Superposition (central image) of the segmented density of the empty N379 helical structure
(transparent gray) with that of the authentic nucleocapsid (cyan). (B) The coordinates of PIV5 N
without RNA (red ribbon) were superimposed with the segmented density. Half of the segmented
density was removed by slicing through the center. The loop-helix α7 region is labeled. The cleft
in the MuV density corresponds to the location where the RNA would be released. (C)
Superposition of the segmented density of the empty N379 helical structure (gray) with the helical
density of the authentic nucleocapsid (cyan). The density of the authentic nucleocapsid is clipped
through the center.
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Figure 3-2 Comparing empty capsid with that of the authentic
(A) Superposition (central image) of the segmented density of the empty N379 helical structure
(transparent gray) with that of the authentic nucleocapsid (cyan). (B) The coordinates of PIV5 N
without RNA (red ribbon) were superimposed with the segmented density. Half of the segmented
density was removed by slicing through the center. The loop-helix α7 region is labeled. The cleft
in the MuV density corresponds to the location where the RNA would be released. (C)
Superposition of the segmented density of the empty N379 helical structure (gray) with the helical
density of the authentic nucleocapsid (cyan). The density of the authentic nucleocapsid is clipped
through the center.
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Figure 3-3 RNA binding per N subunit
(A) Ribbon drawing of the PIV5 N structure (4XJN) colored by the B factor (side view). The blue
color corresponds to a low B factor, whereas the red color corresponds to a high B factor. N and
C, N terminus and C terminus, respectively, of the PIV5 N-RNA complex. The encapsidated RNA
is shown for one N subunit as a stick model. Residues Ala197 and Gln200 are displayed as sticks
and labeled. Residue Tyr185 is not present in the crystal structure. (B) A close-up view of helix
α7 and the loop prior to helix α7 in the PIV5 N structure. Residues Lys180 and Ala192 are at
each end of this flexible region. Disordered residues183 to 186 are not present. (C) Ribbon
drawings to illustrate the motion required to fit the coordinates of NiV N (PDB code 4CO6) with
the density of the empty N379 helical complex. The structure of NiV N is represented by a ribbon
in cyan. The structure of PIV5 N as fitted in the density of the empty N379 helical complex is
represented by a ribbon colored from blue to red by B factors. The view is approximately down
the axis of the empty N379 helical complex. The C-terminal domains of the two structures were
superimposed together. The red arrow indicates the rotational motion required for the Nterminal domain of NiV N to be superimposed with that of PIV5 N. N and C, N and C termini of
PIV5 N, respectively. RNA is encapsidated in the center of PIV5 N. (D) Ribbon drawing of the
NiV N structure colored by the B factor (side view). The blue color corresponds to a low B
factor, whereas the red color corresponds to a high B factor. N and C, N terminus and C
terminus, respectively.
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Figure 3-4 Minigenome assay of mutants
(A) Expression levels of the mutated MuV N proteins detected by Western blotting, compared
with that of wt MuV N. The full-length N protein was used for quantitation. (B) Activities of the
minigenome reporter gene when the mutated MuV N proteins were used in the system. wt MuV N
was used as the positive control.
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4. PROBING THE ROLE OF THE PHOSPHOPROTEIN AMINO TERMINAL END IN
THE UNCOILING OF THE NUCLEOCAPSID

Chelsea Severin and Ming Luo

4.1

Abstract
Paramyxovirus genome synthesis involves specific interactions between the large protein,

the phosphoprotein (P) and the helical viral ribonucleoprotein (vRNP) complex. The binding
activity of P is necessary to dock the nucleocapsid (N) protein coated RNA to the large protein
for viral replication. Previously, we have shown in mumps virus (MuV) that the amino terminal
domain of P binds to a nucleocapsid-like particle (NLP) and induces uncoiling of the authentic
nucleocapsid (40, 75). However, the actual region of the P N-terminal domain (PNTD) involved in
this interaction has not been determined. Here, we sought to delineate the specific residues of
PNTD involved in the uncoiling of the viral genome. We have developed an in silico model of the
MuV NLP-PNTD complex and have identified a region within PNTD which is necessary for
interaction with the NLP. Using site directed mutagenesis and binding assays we have identified
residues which are necessary for binding to the NLP. This work provides insights into the
mechanism of the polymerase activity of P.
4.2

Introduction
The Paramyxoviridae family of viruses include many pathogens which are infamous for

their toll on public health and the agricultural economy. This group includes many notable
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viruses such as mumps virus (MuV), parainfluenza viruses, measles virus (MeV), and Nipah
virus (NiV). Due to their single strand negative polarity RNA genome, paramyxoviruses can be
further categorized into the broad group of negative stranded RNA viruses (NSVs). The
paramyxovirus RNA genome is non-segmented and about 15 kb in length. The viral genome is
always coated by the N protein to form a helical viral ribonucleoprotein (vRNP) and this
complex is the active transcript for viral replication and transcription. For efficient infection in
host cells, paramyxoviruses require interaction between the viral RNA dependent RNA
polymerase (vRdRp) and the helical vRNP. The vRdRp is a complex formed between the large
(L) protein and the phosphoprotein (P). Catalytic activity of the polymerase resides in L while P
is necessary for recognizing the N-RNA complex for transcription and replication.
During viral RNA synthesis, P must recognize the nucleocapsid and remain associated
with the N protein as the polymerase moves across the viral genome. The location of the
nucleocapsid binding domain on several paramyxoviruses and other NSVs have been mapped. In
vesicular stomatitis virus (VSV) of the Rhabdoviridae family, the C-terminal domain of P binds
to the C-terminal domain of two adjacent N protomers within the nucleocapsid like particle (66).
As a chaperone, P also tethers to soluble, monomeric N to prevent illegitimate interactions with
cellular RNA and nascent N-N oligomerization. Upon a switch from transcriptase to replicase
mode which is believed to be modulated by the concentration of free N protein, a conformational
change in the interaction between N and P allows the monomeric N protein (N 0) to encapsidate
the newly formed viral RNA. In paramyxoviruses, the N-terminal domain has been purported to
play a role in N0-P binding. High resolution structures of MeV, PIV5 and NiV have indicated
that the amino terminal end of the phosphoprotein binds to the C-terminal end of the
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nucleocapsid (70, 82, 83). Examination of these structures further suggest that binding of P to the
nucleocapsid like particles induces conformational changes in the RNA binding groove.
The P protein of MuV is a highly phosphorylated tetramer composed of an N-terminal
region (aa 1-194), a central core region which has an oligomerization domain (aa 213-277) and a
C-terminal domain (aa 277-391) (75). The amino terminus contains the binding site of polo-like
kinase I which phosphorylates S292/S294 in the C-terminal domain of P(84). In other
paramyxoviruses, the N-terminal domain of P is responsible for preventing N from binding to
cellular RNA. The nucleocapsid binding site has been mapped to the C-terminal end of the
protein. The structure of the oligomerization domain reveals a novel structure with two pairs of
anti-parallel alpha helices which position two amino terminal and two carboxy terminal ends at
each end of the tetramer(75). Studies have shown that the oligomeric state of the protein is
necessary for viral replication which suggests that MuV might possess a unique method of
replication.
During the replication cycle, the viral genome is always associated with the nucleocapsid
protein. This encapsidated RNA is the active template for transcription which P recognizes. The
N protein of MuV is comprised of two domains: an N-terminal core and a C-terminal tail(68).
The N-terminal domain is responsible for binding to the polymerase and RNA encapsidation.
The carboxy end of P binds to the N-terminal domain of the nucleocapsid core in MuV and other
paramyxoviruses. When expressed in bacterial systems, nucleocapsid proteins tend to bind to
non-specific RNA and form ring structures which represent one turn of the helical nucleocapsid.
Structures of nucleocapsid-like particles (NLPs) have been solved for various negative strand
RNA viruses such as respiratory syntactical virus (RSV), VSV and more recently Parainfluenza
virus 5 (61, 63, 85). Parainfluenza virus 5 (PIV5) is a member of the Paramyxoviridae family
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which shares about 42% sequence homology with MuV. The structure of a PIV5 NLP lacking
the C-terminal tail revealed that the nucleocapsid-like structure is a 13-mer ring which consists
of a core region flanked by a N-arm and C-arm at its N-terminal and C-terminal ends
respectively. The RNA is sequestered between the N-terminal and C-terminal domains of the Ncore where each monomer binds exactly six nucleotides.
Several studies have sought to determine the mechanism of interaction between the
nucleocapsid and phosphoprotein domains in paramyxoviruses. To date, the body of work
available on the N-P complex focuses primarily on the interaction between the monomeric form
of N and N-terminal peptides of P. However, the actual residues involved in docking the
nucleocapsid to the polymerase is still unclear. Here, we utilize homology models and rational
mutagenesis to identify important residues in an amino terminal fragment of the phosphoprotein
which are important for interaction with a NLP of MuV. The data implicates critical residues in
the N-terminal domain of the phosphoprotein are necessary for binding the NLP. Furthermore,
these new insights will allow the rational design for antivirals that target the polymerase
complex.
4.3
4.3.1

Materials and Methods
Molecular Biology
The genes encoding N and PNTD were previously cloned into pet28B vector (68, 75).

Briefly, the NLP was expressed using a pet28b vector which was designed to coexpress the N
and P proteins in equimolar ratios with an N-terminal His tag residing on the P gene. Constructs
of the N-terminal fragment of P and its alanine mutants were generated by site directed
mutagenesis of the P NTD plasmid using Phusion site directed mutagenesis kit (ThermoFisher)
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according to the manufacturer’s protocol. All plasmids were verified by sequencing (Eurofins
Genomics).
4.3.2

Computer aided studies
Predictive 3D structures of the NLP and P110 were generated using MODELLER 9.20

(86). The structures of PIV5 NLP and PIV5 V were used as templates for the models of MuV
NCORE (1-401) and P110 (aa 1-110) respectively (39, 87). Alignment of the target and template
sequences were generated using python script salign.py with MODELLER. The alignment file
was used to generate 10 models of the target protein, of which the structure with the lowest
discrete optimized protein energy (DOPE) score was selected for further model validation. The
selected model was evaluated using PROCHECK(88) and the Ramachandran plot was used to
examine the dihedral angles of the residues to assess the quality of the models. The best models
of NCORE and P110 were used to perform docking studies of the proteins using HADDOCK2.2
(89) server. The active and passive residues were defined based on the structure of the PIV5 N 0P50 structure. The highest ranked models were visually inspected, and the best model was
selected.
4.3.3

Protein expression and purification
Plasmids harboring genes encoding either the N/P genes or P110 wild type and mutant

proteins were transformed into Escherichia coli Rosetta DE3 cells. A starter culture was grown
overnight in 2x YT medium supplemented with 50 µg/µl of kanamycin. This starter culture was
used to inoculate 1 L of medium containing 50 µg/µl of kanamycin and the cells were grown at
37 °C until the OD was between 0.6 and 0.8. Protein expression was induced with 1 mM
isopropyl β-D-1-thiogalactopyranoside at 25 °C for 16 h or 18 °C for 18 h for the N and P110
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mutants respectively. The bacteria were harvested by centrifugation at 4000 rpm and stored at 80 °C.
For protein purification of the P110 wild type and variant proteins, bacterial cells
expressing the protein of interest were resuspended in binding buffer A containing 50 mM Tris
(pH 8), 500 mM NaCl, 5 mM Imidazole, 5 mM -mercaptoethanol (-ME) and 5% glycerol. The
cells were lysed by sonication after which the insoluble cell debris was separated by
centrifugation at 18000 rpm for 45 min. The cleared lysate was loaded onto a 5 ml HisTrap HP
Ni affinity column (GE Healthcare) which had been equilibrated with binding buffer A. The
column was washed to UV baseline with binding buffer. Non-specifically bound proteins were
eluted in 5 column volumes (CV) of washing buffer (50 mM Tris pH 8, 500 mM NaCl, 50 mM
imidazole, 5 mm -ME, 5% glycerol). The protein was eluted from the column in 5 CV of
elution buffer containing 50 mM tris pH 8, 500 mM NaCl, 500 mM imidazole, 5 mm -ME and
5% glycerol. Size exclusion chromatography (Superdex 75; GE Healthcare) was used as a
polishing step and the protein of interest was eluted in buffer containing 20 mM Tris (pH 8) and
150 mM NaCl.
The N protein was purified by Ni affinity column using the same protocol described
above for the P110 wild type and mutants. To separate the N and P proteins the fractions from
the elution step were pooled together and dialyzed overnight at 4 °C against buffer A8.3
containing 50 mM tris (pH 8.3) and 150 mM NaCl for ion exchange chromatography. The
dialyzed protein was loaded onto a 5 ml Hitrap Q HP column (GE Healthcare) that had been
equilibrated with buffer A8.3 and the column was washed to UV baseline with binding buffer
A8.3. The protein was eluted in a step gradient of 20%, 40%, 66%, 75% and 100% B, where
buffer B8.3 contained 50 mM Tris (pH 8.3) and 750 mM NaCl. The fractions from the 66% B
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step were pooled together and concentrated with an Amicon centrifugal filter. The concentrated
protein was loaded onto a Superose 6 16/600 (GE Healthcare) that had been equilibrated with 20
mM Tris (pH 8) and 150 mM NaCl.
4.3.4

Protein binding assay
To probe the interactions between the NLP and P110 or NLP and P110 alanine mutants a

His6 pulldown assay was performed. To 50 μl of HisPur NiNTA resin (ThermoFisher), 50 μg of
P110 or P110 variants was added and incubated at room temperature for 30 min. The beads were
spun down at 4000 rpm for 5 min and the supernatant discarded. The beads were washed with
buffer containing 20 mM Tris, 50 mM NaCl and 5 mM imidazole. The NLP (50 μg) was added
to the beads and incubated at room temperature for 30 min under rotation. The beads were
washed with binding buffer B and the proteins were eluted with binding buffer B containing 20
mM Tris pH8, 50 mM NaCl and 500 mM Imidazole. The samples were electrophoresed on a
12% SDS-PAGE gel and visualized with Coomassie blue staining. Non-specific binding of the
NLP was assessed in the absence of P110 protein.
4.3.5

Thermal shift assay
Thermal scanning was used to further investigate the effect of the mutations on the NLP-

P110 complex. NLP and P110 wild type or mutant proteins were incubated at room temperature
for 30 min at a 3:1 P to N molar ratio to ensure complete binding. Solutions of 20 µl of protein
sample per well were prepared by mixing 2 µl of 100X Sypro Orange or Sybr Safe with the
protein mixture. The samples were set up in triplicates in a Microamp fast 96 well plate (Thermo
Fisher) sealed with optical quality sealing film. The thermal shift assay (TSA) was performed on
a Step One Real Time PCR instrument where the temperature was increased with a gradient from
25 to 95 ºC with a ramp rate of 1%. Raw data was analyzed in MATLAB and smoothed using
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Savitzky-Golay method. The normalized data was used to plot first derivative graphs of
florescence vs temperature and to identify the melting temperature of the protein.
4.4
4.4.1

Results
Identification of N-terminal residues of P involved in the potential NLP binding site
The full-length P protein consists of three independent domains: the amino terminal

domain, the core oligomerization domain and the C-terminal domain. We were the first to
illustrate that the N-terminal end of the phosphoprotein interacts with the NLP and the authentic
viral nucleocapsid of a negative stranded RNA virus. Here, we utilized computer simulations to
identify the important residues of the first 110 amino acids of P. The only available 3D structure
with significant sequence homology to MuV N and P110 is that of PIV5. Residues 3 to 401 of
MuV N were aligned with residues 3 to 401 of PIV5 NCORE structure (PDB 4XJN). MODELLER
9.20 was used to generate 10 models of a N homotrimer of which the model with the lowest
DOPE score was selected. The DOPE score represents the highest ranked model. The model was
further subjected to validation using PROCHECK. The model had approximated 92% of amino
acids falling in the core region, which indicates that the structure is a good quality model. PIV5
V protein was aligned with the protein sequence P110 and showed a sequence identity of 50%.
The P110 model was also generated by MODELLER 9.20 and assessed by PROCHECK. The
Ramachandran plot indicates that 85.3% of the residues are in most favored regions, 13.3% are
in additional allowed regions and 1.3% are in generously allowed regions.
Utilizing these computer generated structures, we docked the homology models of NCORE
and P110 using HADDOCK. The structure of PIV5 monomeric N bound to a 50-residue long Nterminal P fragment was recently determined. The 3D structure indicates that the contacts
between the PIV5 protein are both hydrophobic and polar. We examined the structure of the
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PIV5 NCORE-P50 complex and our docked structure and identified region consisting of amino
acids 13-19 (except G17, M18) as necessary for the P110-NLP interaction (Figure 4-1). P110
variants were expressed and purified using the same methods as the wt protein. The yield of
protein per liter varied for three of the variants. Proteins harboring the L13A and I14A mutations
had a greater yield than that of the wt; whereas, N19A had a decrease in expression.
4.4.2

Residues in loop are necessary for NLP-P110 interaction in pulldown assay
To determine the effects of the identified residues on the interaction between P110 and

NLP, alanine mutants were analyzed in a pulldown assay (Figure 4-2). The proteins were
expressed in E coli with the 6X N-terminal His tag residing on the P110 protein. Purified P110
wild type or alanine mutants were added to a NiNTA beads and then incubated with the NLP.
The bound proteins were eluted and visualized. The experiment confirmed that the P110 wt
protein binds to NLP. We also determined that residues L13 and I14 were necessary for
interactions with the NLP. Point mutations of these residues to alanine disrupted binding to the
NLP.
4.4.3

Effects of targeted mutations on thermal stability of NLP-P110 interaction
To further investigate the effects of the alanine mutations on the NLP-P110 interactions

we used a thermal shift assay to determine the impact of P110 on the thermal stability of the
NLP. Previously, we have used stability shift analyses to quantify the interactions between VSV
NLP and a polyamide (90). Here, a similar approach was used to assess the interactions between
the MuV NLP and P110. The protein samples were incubated with a fluorescent dye, Sypro
Orange. The melting curve plot shows changes in the fluorescence of the Sypro Orange dye as
temperature increases. In this study, we define Tm as the temperature at which the change rate of
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fluorescence is at maximum, indicating that increasing hydrophobic sites are exposed. Under our
experimental conditions, the NLP exhibits a Tm of 70.3 °C (Figure 4-3).
Previously, we have shown that the N-terminal domain of the phosphoprotein can unwind
the authentic nucleocapsid and NLP. It follows then that upon binding to the NLP the N-terminal
domain of P should destabilize the protein and decrease the Tm. Upon binding to the NLP, the
P110 protein decreased the Tm by 0.5 °C (Figure 4-3). Proteins harboring mutations L13A and
I14A did not have statistically significant effect on the Tm. Interestingly, the N19A mutation
decreased the Tm by 1°C to 69.2°C suggesting that this mutation enhanced the destabilization of
the NLP.
4.4.4

Alanine variants affect the thermal release of RNA from the NLP
The nucleocapsid protein effectively protects the viral RNA from degradation by

formation of helical structures. However, it was shown that RNA loss in the NLP is dependent
on pH, temperature and ionic strength. Under thermal denaturation conditions, the NLP
undergoes changes to reveal the hydrophobic core; therefore, it is expected that at a point prior to
unfolding a conformational change in the protein will encourage the release of the encapsidated
RNA. The accessibility of the encapsidated RNA might be therefore monitored using a
fluorescent dye which intercalates with nucleic acid. We define the approximated temperature at
which the RNA is released from the NLP (TR) as the peak in the second derivative plot at which
the change of the change rate of fluorescence is at maximum.
Analysis of the NLP melting curve when monitored by Sybr Safe has a high initial
fluorescence most likely due to tight binding of the dye intercalating between the stacked bases
of RNA within the NLP. The thermal release of RNA, TR, observed from the experiment was
measured as 68.1 °C (Figure 4-3;Table 4-1). This result was consistent with previous studies
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(68). In the presence of the amino terminal fragment of P, the observed TR decreased by 0.7 °C to
67.5 °C, suggesting that P110 binding of NLP facilitates RNA release. Variants L13A and I14A
had no effect on the thermal release of RNA from the NLP; while, N19A decreased the TR by
2.0°C to 66.1°C.
4.5

Discussion
During viral replication, only the encapsidated viral genome can be used for viral RNA

synthesis. The intimate interaction between the N protein which coats the viral genome and the
polymerase cofactor P is critical for this process. To effectively design therapeutics that target
these viruses identification of the binding mode of this N-P interaction is necessary. However,
obtaining high resolution structures of the N-P complex has proven to be difficult due to
flexibility in the proteins. The MuV nucleocapsid binding domains has been mapped to the Nterminal and C-terminal domains of MuV P(75). When visualized by negative stain, in the
presence of the N-terminal domain of P, the authentic nucleocapsid was unwound indicating that
this domain is necessary for unveiling the viral RNA (40). Here, we sought to delineate the
residues in the N-terminal domain of P which are necessary for binding the nucleocapsid.
Our model of the nucleocapsid-phosphoprotein complex illustrates that a loop consisting
of the first 19 aa sits between the interface of the lobes/arms of the nucleocapsid protein. These
arms have been illustrated to be necessary for oligomerization of the nucleocapsid protein
subunits in PIV5 and VSV(39, 61). Therefore, it is plausible that the N-terminal domain of P
might sit in the interface and disrupt the interactions between N and N+1.To identify amino acid
residues in this domain which are involved in the interaction with the NLP binding to facilitate
RNA release studies were carried out using recombinantly expressed proteins. We designed
alanine mutants of residues D12, L13, I14, E15, T16 and N19 in P110 to assess the effects of

75
these mutations on NLP binding. In our interaction assay, proteins harboring the L13A and I14A
mutations did not pull down the NLP (Figure 4-2).
Binding of P110 to the NLP should cause a structural change in the protein and affect its
thermal stability. To assay this change, we monitored the interactions of the proteins using the
fluorescent dye Sypro Orange. In the presence of P110 the melting temperature of the NLP
decreased by 0.5 °C. The decrease in the Tm of the NLP suggests that P destabilizes the NLP.
This data is consistent with previous studies which show that the N-terminal domain of P uncoils
the nucleocapsid protein. Proteins harboring either L13A or I14A had no effect on the thermal
stability of the NLP most likely due to the loss of interaction between the proteins.
To further characterize the effect on RNA release from the NLP we used a thermal shift
assay to monitor RNA release using Sybr Safe. When intercalated between bases in nucleic
acids, Sybr Safe dye has fluorescence excitation maxima at 280 and 502 nm and an emission
maximum at 530 nm. We applied this property to the TSA to determine the temperature at which
RNA is released from the NLP. The crystal structure of PIV5 NLP indicates that the RNA strand
sits in a polar groove in which the bases are stacked. In the NLP, the environmentally sensitive
dye, Sybr Safe, intercalates between the stacked bases of the encapsidated RNA. Since the
concentration of RNA is high within the ring, it is expected that the initial fluorescence of Sybr
Safe would be high (Figure 4-3). The first derivative plot of Sybr Safe fluorescence quantifies
the rate of fluorescence change as a function of temperature. Fluorescence emission initially
decreases with increasing temperature which represents the release of dye molecules. The
fluorescence intensity begins to increase later because the dye is able to intercalate more
efficiently into the sequestered RNA at a more appropriate temperature. At a turning point, the
fluorescence signal is decreased due to release of the single stranded RNA which has no
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structure and thus the dye is unable to intercalate between the stacked bases. The point at which
fluorescence change rate is maximum is denoted as TR, as observed in the second derivative
graphs
The release of nucleic acid (TR) and protein melting (Tm) temperature of the NLP were
found to be distinct at 68.1°C and 70.3 °C, respectively. This observation is in agreement with
structural data which indicates that the sequestered RNA sits within a polar pocket in the NLP.
From the second derivative graph, it was determined that the release of the RNA from the NLP
in the presence of P110 was reduced by 0.7°C. However, in the presence of L13A and I14A the
release of sequestered RNA was unaffected, which confirms our above results which indicate
that these residues abrogate binding of P110 to the NLP.
The MuV P protein is transcribed from the V/P/I gene from a shift in the ORF by
insertion of two guanine residues. The V protein is the faithful transcript of the V/P/I gene and V
is thought to be necessary for evasion of the host immune responses. P and V share an Nterminal domain; therefore, it is possible that these residues serve as regulation of the viral
replication by the V protein. Previously it was shown in PIV5 that the same residues (L16 and
I17 in PIV5) are necessary for the V-NP interaction. Furthermore, it was illustrated that these
two residues were critical for the inhibitory activity of V in the minigenome system.
The N-terminal domain of P relaxes the nucleocapsid of MuV. We believe that this
interaction is necessary to facilitate the release of the encapsidated viral RNA from the
nucleocapsid complex. Here, we have identified residues in the amino terminus of P which are
important for binding to the NLP. To our knowledge, this is the first study in which the critical
residues in the NP-P interaction were identified.
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A

B

Figure 4-1 Homology Model of NCORE-P110 complex.
(A)MuV NLP-P110 model as determined by HADDOCK. (B) Potential site of interaction
between NLP core and P110 according to in silico model.
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T16A
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36
26
20

NLP
85

L13A
− +

I14A
− +
←NLP

47
36
26
20

Figure 4-2 Pulldown assay
Interaction of NLP with P110 variants in a pulldown assay. Proteins harboring L13A and I14A
were unable to pulldown NLP.
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Figure 4-3 Thermal Stability Assay
Melt curve analyses of NLP alone and together with P110 alanine mutants as monitored by
Sypro Orange (black) and Sybr Safe (gray) dyes (column one). The first derivatives of curves in
column one were plotted for Sypro Orange (column two) and second derivatives were plotted for
Sybr Safe (column three). The Tm was determined as the maxima from the plots in column two,
whereas the TR was determined as the maxima from the plots in column three. Errors are shown
as standard deviations from triplet experiments.
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Table 4-1 Summary of Affinities and Thermal Release of RNA
Sample
TRa
ΔTR
Disruption of binding in pulldown assay?
NLP

68.13 (0.03)

-

-

P110

67.46 (0.25)

-0.67

-

D12A

67.65 (0.19)

-0.48

No

L13A

68.24 (0.20)

0.11

Yes

I14A

68.13 (0.22)

0.00

Yes

E15A

67.11 (0.19)

-1.02

No

T16A

67.31 (0.03)

-0.82

No

N19A

66.14 (0.46)

-1.99

No

aStandard

deviations indicated in parentheses
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5. RESEARCH CHALLENGES AND IMPACT
5.1

Crystallization of PB2 cap binding protein
Structural determination of the PB2cap binding domain in complex with the m7 GTP

substrate is necessary for rational drug design of inhibitors which target the protein. Crystal
soaking and co-crystallization are common techniques used for structural determination of a
protein-ligand complex. The apo crystals of PB2cap binding protein were grown in buffer
containing 0.1 M HEPES pH 8.0, 20% (w/v) PEG 3350 and 0.2 M magnesium nitrate. However,
when we attempted cocrystallization of the protein-ligand complex together no protein crystals
were obtained from screening. Alternatively, soaking the wild type crystals with the substrate
caused dissolution of the protein crystals. It is possible that crystal packing in the apo crystal
form inhibits the functional binding site of the protein. The structure of the unbound PB2cap
protein alone includes two molecules in the asymmetric unit. In the crystal structure the capbinding site is blocked by a long, flexible loop consisting of aa 421-427 (denoted here as 424loop). To circumvent this, the 424-loop was truncated and replaced by the linker GSG. Utilizing
this loop truncation mutant, cocrystals were obtained of the PB2cap binding protein alone and in
complex with the cap analogue.
5.2

Implications for Design of inhibitors that target influenza viruses A & B
Antigenic variation in influenza A viruses can cause the emergence of novel viruses and

lack of innate immunity against these viruses may cause pandemics. Influenza B viruses also
pose a significant threat since these viruses circulate primarily in humans. In the United States,
the 2019-2020 flu season was characterized by two waves, with influenza B viruses dominating
early in the season and then the A(H1N1)pdm09 virus (91). This confirms that a potent inhibitor
of influenza virus infection should target both types A and B viruses.
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When the structure of the PB2cap of B/Jiangxi/BV/2006 was compared to that of the
2009 pandemic strain, differences in the binding pocket and important interactions were evident.
Firstly, the cap analog, m7 GTP binds further into the binding pocket of PB2cap binding domain
of influenza virus H1N1 A/California/ 07/2009. This suggests that a potent inhibitor against
influenza A and B viruses should fit the pocket of influenza B viruses. Additionally, the structure
of the PB2cap of B/Jiangxi/BV/2006 reveals that His357 of pdm09 strain is replaced by Trp,
which makes more π- π stacking interactions with the guanine moiety. Also, Phe323 of influenza
A is replaced by Gln, which can no longer provide π- π stacking and His432 is replaced by the
bulkier Tyr residue. Our structural analyses of both type A and B PB2cap have laid the
foundation for design of a novel anti-influenza virus therapies.
5.3

Viral RNA sequestered within the Paramyxovirus Nucleocapsid
The viral RdRp of paramyxoviruses uses the encapsidated viral genome for viral

replication and transcription. The viral RNA is always sequestered within the helical
nucleocapsid; therefore, the polymerase complex must somehow open the nucleocapsid.
Utilizing the structure of PIV5 NLP and monomeric NiV N it was proposed that the sequestered
RNA within the nucleocapsid is revealed once the C-terminal domain of N rotates outwards and
allows the polymerase access to the viral genome. Here, cryo-EM was used to analyze the
structure of an empty MuV capsid and determine the most likely model for RNA release. The
coordinates of the PIV5 NLP structure were mapped onto the empty capsid of MuV. The
temperature factor or B factor is a term which reflects the flexibility of different parts of the
molecule. When the coordinates of PIV5 were mapped onto the structure of the NLP it revealed
that it is unlikely that the C-terminal domain would rotate outward to reveal the viral RNA since
this region has low B-factors which suggest high structural stability. Analysis of the structures
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suggest that the loop-helix α7 of MuV N may be required for unveiling the genome due to the
high flexibility in this region. It is likely that the polymerase induces a local conformational
change in the helix α7 region and therefore, N does not need to open a very stable core to reveal
the sequestered RNA.
5.4

Uncoiling the MuV Nucleocapsid
MuV P is necessary for the L protein to gain access to the nucleocapsid for viral

replication. The mechanism by which the vRdRp gains access to the sequestered RNA is not
clearly understood. Previous paramyxovirus models suggest that rotation in the C-terminal
domain would expose the viral genome for the viral polymerase. Crystal structure analysis of
MuV P show that the protein is a tetramer in which P molecules orient in an antiparallel manner.
Additionally, it was shown that the N-terminal domain of P was binds to the authentic
nucleocapsid and induces uncoiling. Therefore, it is plausible that the N- and C- terminal
domains of P cooperatively induce local conformational changes in the nucleocapsid to reveal
the viral genome. The C-terminal domain recognizes the helical nucleocapsid, while the Nterminal domain disrupts the N-N interactions and opens the “gate” to the vRNA. It would be
very difficult for the polymerase alone to unveil the genome.
5.5

Implications for design of antivirals and vaccine development of MuV
The nucleocapsid-phosphoprotein interaction constitutes a reasonable target for design of

antivirals that inhibit viral replication. In RSV, inhibitors which bind to N and compete with P
have been identified. Structural information of the MuV N-P binding will provide an
opportunity to design inhibitors which disrupt this interaction. Furthermore, knowledge about the
replication mechanism will aid in the development of more effective vaccine candidates that are
selected for efficient replication.
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6. CONCLUSIONS
The coronavirus pandemic has exemplified the effects of viruses on public health and
everyday life when unprepared with therapeutics. We need to identify current and emerging
viruses which have the potential to cause pandemics and epidemics. Therapeutics and/or
vaccines that target these pathogens are necessary to combat these viruses. Negative stranded
RNA viruses possess a single stranded viral genome of negative polarity as their genome. The
polymerase is packaged within the virion and is a rational target for drug design. Here, the
polymerase complex of a segmented and unsegmented NSV was structurally and biochemically
probed.
For over 100 years influenza viruses have caused pandemics. Implementation of the
annual flu vaccine has significantly curbed the spread of the virus, but its effectiveness is only as
good as the prediction of viruses that could be circulating during the season. Influenza viruses
are highly mutagenic and consequently there is not a standalone vaccine that can confer
immunity against each virus strain. Current influenza inhibitors on the market target the
glycoproteins that are necessary for viral entry. However, due to the constant antigenic drift in
the stalk proteins, these drugs are losing effectiveness. This suggests that we need to alter our
strategy to target proteins within the virus which are unlikely to develop mutations which would
renter the antiviral useless.
In aim 1, the polymerase complex of influenza virus was identified as a viable target for
design of influenza inhibitors. The PB2cap protein of the polymerase complex, utilizes a cap
snatching mechanism to steal a m7-methyl cap from the host pre-mRNA to cap its viral mRNA.
The structure of the PB2cap binding domain alone and in complex with a cap analog revealed
that it does not make the same interactions as human capping proteins and thus is a viable target.
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Furthermore, the structure of the cap analog of PB2cap from an influenza A and B virus
indicated important interactions for drug design that will confer resistance to both strains.
Mumps virus has been largely controlled by the MMRII vaccine, however, sporadic
outbreaks on university campus highlight the need for therapeutics that target the virus. The
polymerase complex of mumps virus is a complex formed between the Large protein and the
phosphoprotein. The phosphoprotein cofactor acts to home the polymerase onto the helical
nucleocapsid for viral RNA synthesis. Due to the fact that the polymerase complex is not highly
mutagenic, disrupting viral replication and transcription is a viable target for drug design.
Chapter 2 sought to assess the RNA sequester of the nucleocapsid. Using cryo-EM, the
structure of the nucleocapsid-like particle lacking the C-terminal tail was solved to 10.4 A. The
structure of PIV5 nucleocapsid like particle was superimposed upon the cryo-EM structure to
examine the regions of the nucleocapsid involved in RNA release. The alpha7-helix of the
nucleocapsid protein was identified as the most likely region that allows RNA sequester.
The interactions involved in the uncoiling of the nucleocapsid like particle of MuV were
evaluated in specific aim 3. An in silico model of MuV NLP and an amino terminal fragment of
PNTD protein was generated Residues L13 and I14 were identified as important for this
interaction. Furthermore, the results suggest that L13 and I14 are particularly important due to
their effects on thermal release.
The polymerase complex of NSVs is a viable target for drug development. This body of
work unveiled the polymerase complex of influenza virus a sNSV and mumps virus a nsNSV.
This work furthers the available information with regards to the viral proteins involved in viral
replication. Furthermore, emergence of drug-resistant virus strains to polymerase complex
inhibitors will be unlikely due to high sequence conservation in the proteins.
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